[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4917
1. Hasson A, Romero WA: Treatment of facial atrophic scars with Esthélis, a hyaluronic acid filler with polydense cohesive matrix (CPM). J Drugs Dermatol; 2010 Dec;9(12):1507-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Twelve patients aged 18-56 years with facial atrophic scars caused by acne vulgaris, dog bite, piercing, basal cell carcinoma and leishmaniasis were treated with Esthélis.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Chlorobenzenes / therapeutic use. Cicatrix / drug therapy. Drug Delivery Systems. Face. Hyaluronic Acid / therapeutic use. Sulfides / therapeutic use

  • MedlinePlus Health Information. consumer health - Scars.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120258.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorobenzenes; 0 / Excipients; 0 / Sulfides; 123-09-1 / 4-chlorophenyl methyl sulfide; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


2. Marmur ES, Berkowitz EZ, Fuchs BS, Singer GK, Yoo JY: Use of high-frequency, high-resolution ultrasound before Mohs surgery. Dermatol Surg; 2010 Jun;36(6):841-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although ultrasound imaging is employed ubiquitously today, its use to examine and assess the skin is a relatively new technology.
  • For different tumor types, there was no significant difference between clinical and ultrasound widths or lengths for basal cell carcinoma (t=-1.307, p=.23; t=-1.389, p=.20) or squamous cell cancer (t=-0.342, p=.73; t=0.427, p=.68).
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Mohs Surgery. Skin Neoplasms / pathology. Skin Neoplasms / ultrasonography
  • [MeSH-minor] Cohort Studies. Female. Humans. Male. Neoplasm Staging. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618368.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. van den Top JG, de Heer N, Klein WR, Ensink JM: Penile and preputial tumours in the horse: a retrospective study of 114 affected horses. Equine Vet J; 2008 Sep;40(6):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data recorded included age, gelding or stallion and breed; type and site of lesion; involvement of regional lymph nodes; histopathology (including grading of squamous cell carcinoma); and results of radiographic examination of the thorax.
  • Common presenting clinical signs were irregularities (e.g. the presence of a mass and/or ulceration) on the integument of the penis and prepuce, and purulent or sanguineous discharge from preputial orifice.
  • Squamous cell carcinoma (SCC) was the most prevalent neoplasm followed by papillomas and melanomas.
  • A basal cell carcinoma, neurofibrosarcoma, adenocarcinoma or fibrosarcoma were each found on single horses.
  • Squamous cell carcinomas with poor differentiation had a higher tendency to metastasise than did more differentiated tumours.
  • CONCLUSIONS: Squamous cell carcinoma is the most common urogenital tumour of the male horse and occurs primarily in old horses.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Horse Diseases / pathology. Penile Neoplasms / veterinary
  • [MeSH-minor] Age Factors. Animals. Breeding. Horses. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis / diagnosis. Male. Neoplasm Metastasis / diagnosis. Neoplasm Staging / veterinary. Orchiectomy / veterinary. Papilloma / epidemiology. Papilloma / pathology. Papilloma / surgery. Papilloma / veterinary. Pedigree. Penis / pathology. Penis / surgery. Retrospective Studies. Urethra / pathology. Urethra / surgery

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487101.001).
  • [ISSN] 0425-1644
  • [Journal-full-title] Equine veterinary journal
  • [ISO-abbreviation] Equine Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Ikeda M, Yamasaki T, Kaneta C: First-principles analysis of C2H2 molecule diffusion and its dissociation process on the ferromagnetic bcc-Fe110 surface. J Phys Condens Matter; 2010 Sep 29;22(38):384214
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-principles analysis of C2H2 molecule diffusion and its dissociation process on the ferromagnetic bcc-Fe110 surface.
  • Using the projector-augmented plane wave method, we study diffusion and dissociation processes of C(2)H(2) molecules on the ferromagnetic bcc-Fe(110) surface and investigate the formation process of graphene created by C(2)H(2) molecules.
  • In order to study the diffusion process of the C(2)H(2) molecule, the barrier height energies for the C atom, C(2)-dimer and CH as well as the C(2)H(2) molecule are estimated using the nudged elastic band method.
  • The barrier height energy for C(2)H(2) is 0.71 eV and this indicates that the C(2)H(2) diffuses easily on this FM bcc-Fe(110) surface.
  • We further investigate the two step dissociation process of C(2)H(2) on Fe.
  • The first step is the dissociation of C(2)H(2) into C(2)H and H, and the second step is that of C(2)H into C(2) and H.
  • These energies are relatively small compared to the dissociation energy 7.5 eV of C(2)H(2) into C(2)H and H in the vacuum.
  • We further investigate the initial formation process of graphene by increasing the coverage of C(2)H(2).
  • The formation process of the benzene molecule on the FM bcc(110) surface is also discussed.
  • We find that there exists a critical coverage of C(2)H(2) which characterizes the beginning of the formation of the graphene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21386548.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Saran A: Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. Future Oncol; 2010 Jun;6(6):1003-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling.
  • Basal cell carcinoma (BCC) is the most frequent cancer in the white population and its incidence appears to be increasing worldwide.
  • While the majority of BCCs arise sporadically, many cases are attributable to basal cell nevus syndrome, or Gorlin syndrome, an autosomal dominantly inherited disorder characterized by the occurrence of multiple BCCs and by extracutaneous tumors.
  • Genetic studies on patients with basal cell nevus syndrome indicate deregulation of the Hedgehog (Hh) pathway in epidermal keratinocytes as the primary event in the pathogenesis of BCC.
  • This article summarizes the recent progress in understanding Hh-dependent BCC tumorigenesis, as well as evidence for deregulation of other molecular pathways, primarily the Wnt developmental pathway.
  • Understanding the molecular genetics of BCC development has provided new opportunities for molecular therapy of this cancer by targeting Hh and other signaling pathways.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic / genetics. Hedgehog Proteins / physiology. Neoplasm Proteins / physiology. Signal Transduction / physiology. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / pathology. Cilia / physiology. DNA Repair. Forkhead Transcription Factors / physiology. Hair Follicle / growth & development. Humans. Keratinocytes / metabolism. Mammals / genetics. Mice. Mice, Knockout. Mice, Transgenic. PTEN Phosphohydrolase / physiology. Receptors, Cell Surface / deficiency. Receptors, Cell Surface / genetics. Receptors, Cell Surface / physiology. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / physiology. Repressor Proteins / deficiency. Repressor Proteins / genetics. Repressor Proteins / physiology. Skin / growth & development. Wnt Proteins / physiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528237.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Hedgehog Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Repressor Proteins; 0 / SMO protein, human; 0 / SUFU protein, human; 0 / Smo protein, mouse; 0 / Sufu protein, mouse; 0 / Wnt Proteins; 0 / patched receptors; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 150
  •  go-up   go-down


6. Paavilainen V, Aaltonen M, Tuominen J, Saari KM: Histological characteristics of basal cell carcinoma of the eyelid. Ophthalmic Res; 2007;39(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological characteristics of basal cell carcinoma of the eyelid.
  • PURPOSE: To evaluate the histological subtypes of basal cell carcinoma (BCC) of the eyelid and to determine their effect on the size, depth of invasion and need of retreatment of a nonselected patient material seen in south-western Finland.
  • METHODS: We studied the case records and the histological characteristics of BCC of the eyelid treated at the Turku University Eye Clinic during the years 1988 through 1997.
  • The material consisted 103 patients (103 BCC tumors of the eyelid).
  • RESULTS: In 78.3% of the cases, the diameter of the lesion was smaller than 10 mm.
  • The most frequent histological subtype was nodular (84.5%) followed by sclerosing (5.8%), micronodular (4.9%), keratotic (2.9%) and superficial (1.9%) types of BCC of the eyelid.
  • Only patients of the nodular subtype showed recurrences (11 cases).
  • However, some nodular types of BCC tumors smaller than 10 mm in diameter extended to a depth of more than 4.0 mm.
  • CONCLUSIONS: The nodular subtype of BCC should be regarded as a potentially invasive and recurrent tumor.
  • Histopathological examination and subtyping of all BCC tumors is recommended.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164577.001).
  • [ISSN] 0030-3747
  • [Journal-full-title] Ophthalmic research
  • [ISO-abbreviation] Ophthalmic Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Soldano G, Mariscal MM: On the structural and mechanical properties of Fe-filled carbon nanotubes: a computer simulation approach. Nanotechnology; 2009 Apr 22;20(16):165705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have analyzed the effect of different crystal structures of iron (bcc and fcc) inside carbon nanotubes of different topographies.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420578.001).
  • [ISSN] 1361-6528
  • [Journal-full-title] Nanotechnology
  • [ISO-abbreviation] Nanotechnology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Dalmastri C, Pirone L, Tabacchioni S, Bevivino A, Chiarini L: Efficacy of species-specific recA PCR tests in the identification of Burkholderia cepacia complex environmental isolates. FEMS Microbiol Lett; 2005 May 1;246(1):39-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of species-specific recA PCR tests in the identification of Burkholderia cepacia complex environmental isolates.
  • In this study, we evaluated if recA species-specific PCR assays could be successfully applied to identify environmental isolates of the widespread Burkholderia cepacia complex (Bcc) species.
  • A total of 729 Bcc rhizosphere isolates collected in different samplings were assigned to the species B. cepacia genomovar I (61), B. cenocepacia recA lineage IIIB (514), B. ambifaria (124) and B. pyrrocinia (30), by means of recA (RFLP) analysis, and PCR tests were performed to assess sensitivity and specificity of recA species-specific primers pairs. B. cepacia genomovar I specific primers produced the expected amplicon with all isolates of the corresponding species (sensitivity, 100%), and cross-reacted with all B. pyrrocinia isolates.
  • The absence of specific amplification in a high number of B. cenocepacia rhizosphere isolates indicates that recA specific PCR assays can lead to an underestimation of environmental microorganisms belonging to this bacterial species.
  • [MeSH-major] Burkholderia cepacia complex / classification. Burkholderia cepacia complex / isolation & purification. Polymerase Chain Reaction / methods. Rec A Recombinases / genetics. Soil Microbiology. Zea mays / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869960.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; EC 2.7.7.- / Rec A Recombinases
  •  go-up   go-down


9. Gil R, Sabater-Muñoz B, Perez-Brocal V, Silva FJ, Latorre A: Plasmids in the aphid endosymbiont Buchnera aphidicola with the smallest genomes. A puzzling evolutionary story. Gene; 2006 Mar 29;370:17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the analysis of three B. aphidicola strains (BTg, BCt and BCc) belonging to aphids from different tribes of the subfamily Lachninae, that was estimated to harbour the bacteria with the smallest genomes.
  • The presence of both leucine and tryptophan plasmids in BTg, a chimerical leucine-tryptophan plasmid in BCt, and only a leucine plasmid in BCc, indicates the existence of many recombination events in a recA minus bacterium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413149.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acids; EC 2.7.7.- / Rec A Recombinases
  •  go-up   go-down


10. Lee JH, Pyon JK, Kim DW, Lee SH, Nam HS, Kim CH, Kang SG, Lee YJ, Park MY, Jeong DJ, Cho MK: Elevated c-Src and c-Yes expression in malignant skin cancers. J Exp Clin Cancer Res; 2010;29:116
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated c-Src and c-Yes expression in malignant skin cancers.
  • BACKGROUND: Src family kinases (SFKs) play an important role in cancer proliferation, survival, motility, invasiveness, metastasis, and angiogenesis.
  • However, only a few studies have attempted to define the expression and role of c-Src and c-Yes in cutaneous carcinomas.
  • OBJECTIVES: To investigate the expression of c-Src and c-Yes in cutaneous carcinomas to include malignant melanoma (MM), squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).
  • METHODS: We examined 6 normal skin tissues and 18 malignant skin tumor tissues using western blotting for the expression of c-Src and c-Yes.
  • In another set, 16 specimens of MM, 16 SCCs and 16 BCCs were analyzed for the expression of c-Src and c-Yes using immunohistochemical staining.
  • RESULTS: Western blotting showed that c-Src was expressed in all malignant skin tumors, but not in normal skin, while c-Yes was expressed in MM and SCC, but not in BCC and normal skin.
  • Immunohistochemical staining results of c-Src and c-Yes in MM, SCC, and BCC mirrored those of the western blot analysis.
  • CONCLUSIONS: c-Src, rather than c-Yes, plays a key role in the proliferation and progression of malignant skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. Carcinoma, Squamous Cell / enzymology. Melanoma / enzymology. Protein-Tyrosine Kinases / analysis. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-yes / analysis. Skin Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12395-403 [11278729.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):204-12 [19026486.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31574-83 [12771142.001]
  • [Cites] J Biol Chem. 1986 Oct 15;261(29):13754-9 [3093483.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):235-40 [2431764.001]
  • [Cites] Oncogene Res. 1987 Jul;1(2):149-68 [2453014.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):815-21 [1381724.001]
  • [Cites] Cell Growth Differ. 1992 Jul;3(7):435-42 [1384653.001]
  • [Cites] Oncogene. 1993 Oct;8(10):2637-44 [7690926.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):217-26 [8599733.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:513-609 [9442882.001]
  • [Cites] Oncogene. 1998 Jun 25;16(25):3253-60 [9681823.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 3;341(1):73-81 [16412380.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4284-91 [18594011.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4336-44 [18594017.001]
  • [Cites] J Transl Med. 2008;6:53 [18823558.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Apr;127(4):226-30 [11315256.001]
  • (PMID = 20796316.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / CSK tyrosine-protein kinase; EC 2.7.10.2 / Proto-Oncogene Proteins c-yes; EC 2.7.10.2 / YES1 protein, human; EC 2.7.10.2 / src-Family Kinases
  • [Other-IDs] NLM/ PMC2936336
  •  go-up   go-down


11. Fresini A, Rossiello L, Severino BU, Del Prete M, Satriano RA: Giant basal cell carcinoma. Skinmed; 2007 Jul-Aug;6(4):204-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma.
  • Perilesional skin appeared edematous, probably owing to inflammation and impaired lymphatic flow.
  • Histologic examination of a biopsy specimen taken from the margin of the lesion displayed a superficial area of ulceration and invasion of the deeper dermis and subcutaneous tissue (Figure 2A and Figure 2B).
  • Therefore, a diagnosis of basal cell carcinoma, adenoid subtype, was made.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618177.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kitajima A, Amano S, Sakurai K, Enomoto K, Matsuo S, Negishi N, Oinuma T, Nemoto N: [A case of breast cancer detected by MRI mammography after Hollywood syndrome]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1786-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of breast cancer detected by MRI mammography after Hollywood syndrome].
  • A-64-year-old woman, who had been treated with augmentation mammaplasty 40 years ago, came to our hospital complaining of left breast pain.
  • The mass was ill-defined, located in the upper outer quadrant area of her breast, and was 2 cm in diameter.
  • The diagnosis was Class IV by the fine needle aspiration biopsy cytology.
  • We diagnosed the left breast cancer being in T2N0M0, Stage IIA, then we carried out Bt (Auchincloss method) and Sentinel lymph node biopsy (SLNB).
  • There were metastatic cancer cells in the sentinel lymph node.
  • The histological diagnosis was papillotubular carcinoma, f+, n+ (8/11).
  • There was paraffinoma in the non-cancer area.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Implants. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Magnetic Resonance Imaging


13. Dixit S, Acharya S, Dixit PB: Multiple odontogenic keratocysts associated with Gorlin-Goltz syndrome. Kathmandu Univ Med J (KUMJ); 2009 Oct-Dec;7(28):414-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gorlin-Goltz syndrome or Nevoid basal cell carcinoma syndrome is an autosomal dominant disorder with a predisposition to cancer.
  • Features like basal cell carcinoma, odontogenic keratocysts, calcification of falx cerebri, bifid ribs, pits on palms and soles and hypertelorism are evident.
  • A case of this rare disease seen on a 13 year old female patient is presented here, where multiple odontogenic keratocysts were causing disfigurement of the lower jaw as well as displacement and malocclusion of the lower teeth.
  • [MeSH-major] Focal Dermal Hypoplasia / diagnosis. Mandibular Diseases / radiography. Odontogenic Cysts / radiography
  • [MeSH-minor] Adolescent. Basal Cell Nevus Syndrome / complications. Basal Cell Nevus Syndrome / radiography. Basal Cell Nevus Syndrome / surgery. Female. Follow-Up Studies. Humans. Rare Diseases. Risk Assessment. Severity of Illness Index. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502085.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


14. Queille S, Luron L, Spatz A, Avril MF, Ribrag V, Duvillard P, Hiesse C, Sarasin A, Armand JP, Daya-Grosjean L: Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. Carcinogenesis; 2007 Mar;28(3):724-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.
  • Immunosuppressed renal transplant recipients (RTRs) are predisposed to non-melanoma skin cancers (NMSCs), predominantly squamous cell carcinomas (SCCs).
  • We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
  • We found 8 p53 mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that p53 mutations are early events in RTR skin carcinogenesis.
  • HPV DNA was detected in 78% of skin lesions (60% Basal Cell Carcinomas, 82%AK and 79% SCCs).
  • Thus, immunosuppression has increased the risk of infections by HPVs, predominantly epidermodysplasia verruciformis, speculated to play a role in skin cancer development.
  • The p53 mutation spectrum, presenting a high level of CC to TT mutations, shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the skin carcinogenesis of RTRs.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Genes, p53. Immunosuppression / adverse effects. Kidney Transplantation / immunology. Polymorphism, Genetic. Skin Neoplasms / epidemiology. Ultraviolet Rays


15. Smith JH, Padnick-Silver L, Newlin A, Rhodes K, Rubinstein WS: Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Ophthalmology; 2007 Apr;114(4):774-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Family-based case report with detailed clinical and genetic evaluation.
  • METHODS: Evaluation of a large sibship via family history, complete eye and skin examinations, environmental risk factor questionnaire, and genetic testing, as well as a MEDLINE search of familial uveal melanoma kindreds.
  • MAIN OUTCOME MEASURES: Cutaneous and ocular nevi, benign and malignant neoplasms of skin and other sites, brief skin cancer risk assessment tool risk classification for cutaneous melanoma, DNA sequencing of p16INK4a and p14ARF genes, and citations on familial uveal melanoma.
  • RESULTS: The proband and his mother had uveal melanoma, 3 cutaneous melanomas occurred among 2 siblings, and 2 other siblings had basal cell carcinomas.
  • Of the 3 subjects without nevi, 2 had histories of eye or skin malignancies (1 uveal melanoma, 1 basal cell carcinoma).
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Melanoma / genetics. Nevus, Pigmented / genetics. Skin Neoplasms / genetics. Uveal Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Pedigree. Risk Factors. Sequence Analysis, DNA. Surveys and Questionnaires. Tumor Suppressor Protein p14ARF / genetics


16. Holsinger FC, Hafemeister AC, Hicks MJ, Sulek M, Huh WW, Friedman EM: Differential diagnosis of pediatric tumors of the nasal cavity and paranasal sinuses: a 45-year multi-institutional review. Ear Nose Throat J; 2010 Nov;89(11):534-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of pediatric tumors of the nasal cavity and paranasal sinuses: a 45-year multi-institutional review.
  • We conducted a retrospective case-series review to identify the various diagnoses of neoplasms of the nasal cavity and paranasal sinuses in a pediatric population.
  • Lesions included adnexal neoplasm, ameloblastic fibro-odontoma, basal cell carcinoma, benign fibrous histiocytoma, blue nevus, chondrosarcoma, compound nevus, epithelioma adenoides cysticum, esthesioneuroblastoma, Ewing sarcoma, fibrosarcoma, giant cell granuloma, granulocytic sarcoma, hemangioma, hemangiopericytoma, Langerhans cell histiocytosis, lymphangioma, lymphoma, melanoma, neuroblastoma, neurofibroma, ossifying osteofibroma, osteochondroma, osteosarcoma, port wine stain, rhabdomyosarcoma, Spitz nevus, and xanthogranuloma.
  • We believe that the large size of this study and the data on disease incidence will allow clinicians to be better informed of the differential diagnosis of neoplasms of the nasal cavity and paranasal sinuses in the pediatric population.


17. Murphy JG, Lonsdale R, Premachandra D, Hellquist HB: Salivary hybrid tumour: adenoid cystic carcinoma and basal cell adenocarcinoma. Virchows Arch; 2006 Feb;448(2):236-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary hybrid tumour: adenoid cystic carcinoma and basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):494-6 [10747300.001]
  • [Cites] Histopathology. 1999 Oct;35(4):380-3 [10564394.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):698-702 [10420226.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):251-9 [8776422.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Jul;260(6):312-5 [12883954.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):425-8 [15480772.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):724-33 [12118110.001]
  • [Cites] Histopathology. 2000 Sep;37(3):283-4 [10971706.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):495-500 [9230915.001]
  • [Cites] J Korean Med Sci. 2004 Jun;19(3):462-5 [15201517.001]
  • (PMID = 16411133.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


18. Szabo S, Deng X, Khomenko T, Chen L, Tolstanova G, Osapay K, Sandor Z, Xiong X: New molecular mechanisms of duodenal ulceration. Ann N Y Acad Sci; 2007 Oct;1113:238-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with "peptic ulcers" duodenal ulcers are more frequent than gastric ulcers (except in Japan).
  • Thus, our research during the last three decades focused on the molecular mechanisms of duodenal ulcer in rodent models of chemically induced duodenal ulceration, and here we review our three recent findings: Endothelins (ET-1), the immediate early gene egr-1 and imbalance of angiogenic/antiangiogenic molecules.
  • The resulting mucosal necrosis does not rapidly heal because of the imbalance of VEGF and angiostatin/endostatin, hence duodenal ulcers develop.
  • The experimental ulcers Selye described morphologically are now characterized at the molecular and genome level, involving unexpected mediators like ET-1, egr-1 and angiogenesis-related molecules.
  • [MeSH-major] Duodenal Ulcer / etiology. Duodenal Ulcer / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656571.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiogenic Proteins; 0 / Early Growth Response Protein 1; 0 / Endothelin-1
  • [Number-of-references] 78
  •  go-up   go-down


19. Fang JY, Lee WR, Shen SC, Huang YL: Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J Dermatol Sci; 2006 May;42(2):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas.
  • METHOD: Liposomes containing egg phosphatidylcholine, cholesterol, or anionic surfactant in the presence of 15% ethanol were prepared.
  • The liposomes containing EGCG were injected into basal cell carcinomas (BCCs), melanomas, and colon tumors to examine the tumor uptake of the drug.
  • Liposomes were also incubated with a given number of BCC cells, and the cell viability was estimated.
  • RESULT: Almost no drug molecules were observed when free EGCG was administered to BCCs.
  • The liposomes without ethanol showed low or negligible enhancement on EGCG uptake in BCCs.
  • Liposomes protected EGCG from degradation, resulting in the induction of greater BCC death compared to that by free EGCG at lower concentrations.
  • CONCLUSION: These results suggest that the intratumor injection of liposomes containing EGCG with moderate modification is an effective approach for increasing EGCG deposition in BCCs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Catechin / administration & dosage. Catechin / analogs & derivatives. Drug Delivery Systems / methods. Liposomes / chemistry
  • [MeSH-minor] Animals. Cell Line, Tumor. Deoxycholic Acid / chemistry. Ethanol / pharmacology. Female. Humans. Melanoma / metabolism. Mice. Mice, Inbred BALB C. Tea

  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16423506.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Tea; 005990WHZZ / Deoxycholic Acid; 3K9958V90M / Ethanol; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


20. Akhtar K, Zaheer S, Ahmad SS, Hassan MJ: Primary neuroendocrine carcinoma of the breast. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):71-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary neuroendocrine carcinoma of the breast.
  • Primary neuroendocrine carcinoma of the breast is rare-only about 30 cases have been reported in literature.
  • Usually foci of neuroendocrine differentiation can be seen in breast carcinoma and are reported to be present in about 2-5% of breast cancer cases.
  • Here, we report a case of breast carcinoma in which most of the areas studied on the tissue section showed neuroendocrine differentiation.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136787.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


21. Engert S, Wappenschmidt B, Betz B, Kast K, Kutsche M, Hellebrand H, Goecke TO, Kiechle M, Niederacher D, Schmutzler RK, Meindl A: MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. Hum Mutat; 2008 Jul;29(7):948-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
  • Considering only high risk groups for hereditary breast/ovarian cancer, the prevalence of rearrangements is 2.1%.
  • 1) at least two breast cancer cases prior to the age of 51 years;.
  • 2) breast and ovarian cancer cases;.
  • 3) ovarian cancer only families with at least two ovarian cancer cases; or 4) a single breast cancer case prior to the age of 36 years, while no mutations were detected in breast cancer only families with no or only one breast cancer case prior to the age of 51 years.
  • However, in an additional 38 high-risk families with cooccurrence of female breast/ovarian and male breast cancer, one rearrangement in the BRCA2 gene was found.
  • In summary, we advise restricting BRCA1 MLPA screening to those subgroups that revealed LGRs and recommend BRCA2 MLPA screening only for families presenting with cooccurrence of female and male breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Genes, BRCA1. Sequence Deletion


22. van Doorn R, Gruis NA, Willemze R, van der Velden PA, Tensen CP: Aberrant DNA methylation in cutaneous malignancies. Semin Oncol; 2005 Oct;32(5):479-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years it has become evident that in addition to genetic mutations also epigenetic alterations are causally related to the development and progression of cancer.
  • The epigenetic mechanism most relevant in the pathogenesis of cancer appears to be aberrant methylation of tumor-suppressor gene promoters associated with transcriptional downregulation.
  • Malignancies arising in the skin are the most prevalent in humans.
  • The most common are basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (SCC), melanoma, and cutaneous lymphoma.
  • The visibility and accessibility of cutaneous tumors facilitate the scientific study of sequential epigenetic alterations occurring during tumorigenesis and might make treatment of malignant skin lesions using locally applied demethylating agents possible.
  • In this review, we summarize the current knowledge concerning alterations of DNA methylation in BCC, SCC, melanoma, and cutaneous lymphoma.
  • From the limited number of investigations of promoter hypermethylation in cutaneous malignancies, it is already clear that a great number of potential tumor-suppressor genes are epigenetically silenced in skin cancer, including components of signaling pathways critical in the pathogenesis of these malignancies.
  • [MeSH-major] DNA / radiation effects. DNA Methylation. Gene Expression Regulation, Neoplastic. Skin Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Epigenesis, Genetic. Humans. Lymphoma / genetics. Melanoma / genetics. Promoter Regions, Genetic. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210089.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Number-of-references] 95
  •  go-up   go-down


23. Tan TB, Schultz AJ, Kofke DA: Efficient calculation of temperature dependence of solid-phase free energies by overlap sampling coupled with harmonically targeted perturbation. J Chem Phys; 2010 Oct 7;133(13):134104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examine a method for computing the change in free energy with temperature of a crystalline solid.
  • Three exponent values (n=12, 9, and 6) for the potential are studied with different crystal structures, specifically face-centered cubic (fcc), body-centered cubic (bcc), and hexagonal close packing.
  • In particular, for n=12 and 9, the fcc structure is stable for all temperatures up to melting, and for n=6, the bcc crystal becomes stable relative to fcc for temperatures above kT/ε=0.802±0.001.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942520.001).
  • [ISSN] 1089-7690
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Nunan N, Daniell TJ, Singh BK, Papert A, McNicol JW, Prosser JI: Links between plant and rhizoplane bacterial communities in grassland soils, characterized using molecular techniques. Appl Environ Microbiol; 2005 Nov;71(11):6784-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecular analysis of grassland rhizosphere soil has demonstrated complex and diverse bacterial communities, with resultant difficulties in detecting links between plant and bacterial communities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 2003 Dec;69(12):7420-9 [14660394.001]
  • [Cites] Environ Microbiol. 2003 Jun;5(6):441-52 [12755711.001]
  • [Cites] Nucleic Acids Res. 1989 Oct 11;17(19):7843-53 [2798131.001]
  • [Cites] Appl Environ Microbiol. 1993 Mar;59(3):695-700 [7683183.001]
  • [Cites] Appl Environ Microbiol. 1993 Aug;59(8):2657-65 [7690221.001]
  • [Cites] Antonie Van Leeuwenhoek. 1998 Jan;73(1):127-41 [9602286.001]
  • [Cites] Appl Environ Microbiol. 1999 Apr;65(4):1721-30 [10103273.001]
  • [Cites] Curr Opin Microbiol. 1999 Jun;2(3):323-7 [10383864.001]
  • [Cites] Appl Environ Microbiol. 1999 Aug;65(8):3518-25 [10427043.001]
  • [Cites] J Microbiol Methods. 1999 Oct;38(1-2):1-15 [10520580.001]
  • [Cites] FEMS Microbiol Ecol. 2006 Jun;56(3):482-93 [16689879.001]
  • [Cites] FEMS Microbiol Ecol. 2004 May 1;48(2):119-27 [19712395.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4554-9 [11571155.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4742-51 [11571180.001]
  • [Cites] Appl Environ Microbiol. 2001 Dec;67(12):5849-54 [11722945.001]
  • [Cites] Microb Ecol. 2002 Oct;44(3):260-70 [12209255.001]
  • [Cites] Antonie Van Leeuwenhoek. 2002 Aug;81(1-4):509-20 [12448746.001]
  • [Cites] Microb Ecol. 2002 Nov;44(4):296-305 [12375095.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1800-9 [12620873.001]
  • [Cites] BMC Ecol. 2003 Oct 16;3:8 [14563214.001]
  • (PMID = 16269710.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / RNA, Plant; 0 / RNA, Ribosomal, 16S; 0 / RNA, Transfer, Leu; 0 / Soil
  • [Other-IDs] NLM/ PMC1287736
  •  go-up   go-down


25. Payette MJ, Whalen J, Grant-Kels JM: Nutrition and nonmelanoma skin cancers. Clin Dermatol; 2010 Nov-Dec;28(6):650-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutrition and nonmelanoma skin cancers.
  • The incidence of nonmelanoma skin cancer is increasing every year.
  • Basal cell carcinoma and squamous cell carcinoma are the two major types of nonmelanoma skin cancer.
  • Among other factors, understanding the potential role of nutrients in the development, progression, and treatment of nonmelanoma skin cancer is critical.
  • This contribution provides a review of the nutrients that have been more extensively investigated in the literature with regard to nonmelanoma skin cancer, including dietary fats, retinol, carotenoids, vitamin C, vitamin D, vitamin E, selenium, copper, iron, zinc, green tea, and black tea.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Diet. Micronutrients / administration & dosage. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. VITAMIN A .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21034989.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Micronutrients; 0 / Tea; 11103-57-4 / Vitamin A; 1406-16-2 / Vitamin D; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; 789U1901C5 / Copper; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


26. Saldías MS, Ortega X, Valvano MA: Burkholderia cenocepacia O antigen lipopolysaccharide prevents phagocytosis by macrophages and adhesion to epithelial cells. J Med Microbiol; 2009 Dec;58(Pt 12):1542-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic respiratory infections by the Burkholderia cepacia complex (Bcc) are of great concern to patients with cystic fibrosis.
  • Bcc isolates may survive intracellularly within amoebae, respiratory epithelial cells and macrophages.
  • Given the importance of bacterial adhesion to host surfaces in microbial pathogenesis, we investigated the role of the O antigen LPS in the interaction of Burkholderia cenocepacia, a member of the Bcc, with macrophages and epithelial cells.
  • Our results demonstrated that the O antigen modulates phagocytosis but does not affect intracellular survival of B. cenocepacia.
  • We also found that the O antigen interfered with the ability of B. cenocepacia to adhere to bronchial epithelial cells, suggesting that this polysaccharide may mask one or more bacterial surface adhesins.
  • [MeSH-minor] Animals. Cell Line. Lung / cytology. Mice. Mutation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19713359.001).
  • [ISSN] 1473-5644
  • [Journal-full-title] Journal of medical microbiology
  • [ISO-abbreviation] J. Med. Microbiol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O Antigens
  •  go-up   go-down


27. Situm M, Buljan M, Bulat V, Lugović Mihić L, Bolanca Z, Simić D: The role of UV radiation in the development of basal cell carcinoma. Coll Antropol; 2008 Oct;32 Suppl 2:167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of UV radiation in the development of basal cell carcinoma.
  • Basal cell carcinoma (basalioma, BCC) is undoubtedly the most common malignant skin cancer and the most common human malignancy in general, with the continuous increase in its incidence.
  • BCC is generally a disorder of white individuals, especially those with fair skin.
  • UV radiation is the most important risk factor in the development of BCC.
  • Short-wavelength UVB radiation (290-320 nm, sunburn rays) is believed to play a greater role in BCC formation than long-wavelength UVA radiation (320-400 nm, tanning rays).
  • A latency period of 20-50 years is typical between the time of UV damage and the clinical onset of BCC.
  • Therefore, in most cases BCC develops on chronically sun-exposed skin in elderly people, most commonly in the area of head and neck.
  • UVB radiation damages DNA and its repair system and alters the immune system resulting in a progressive genetic alterations and formation of neoplasm.
  • UV-induced mutations in the TP53 tumor-suppressor gene have been found in about 50% of BCC cases.
  • Epidemiologic studies demonstrate the higher incidence of the BCC in more equatorial latitudes than in polar latitudes.
  • Other risk factors for the development of BCC include sun bed use, family history of skin cancers, skin type 1 and 2, immunosuppression, previous radiotherapy, and chronic exposure to toxic substances such as inorganic arsenic.
  • Although rarely metastatic, its malignant nature is sometimes emphasized by the local tissue destruction, disfigurement, and even death if left untreated.
  • Due to extremely high incidence of BCC medical professionals should be aware of the importance of the public education on the etiology of this tumor and the importance of the UV protection.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] DNA Damage. Humans. Receptors, Cell Surface / radiation effects. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138022.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Number-of-references] 29
  •  go-up   go-down


28. Nirmala S, Krishnaswamy M, Janaki MG, Kaushik KS: Unilateral solitary choroid metastasis from breast cancer: rewarding results of external radiotherapy. J Cancer Res Ther; 2008 Oct-Dec;4(4):206-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral solitary choroid metastasis from breast cancer: rewarding results of external radiotherapy.
  • In nearly 85% of cases the choroid is the afflicted site due to its vascularity.
  • Breast and lung are the common primaries.
  • In breast primaries, this could be the first metastatic disease.
  • Fundus examination, ultrasonography and CT/MRI of the orbit help in diagnosis.
  • Here we report a case of unilateral solitary choroid metastasis in a case of breast cancer treated with external beam radiotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Choroid / pathology. Choroid Neoplasms / pathology. Choroid Neoplasms / radiotherapy. Uveal Neoplasms / pathology. Uveal Neoplasms / radiotherapy
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging / methods. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed / methods. Treatment Outcome. Ultrasonography / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052398.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


29. Tai KP, Dai XD, Shen YX, Liu BX: Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation. J Phys Chem B; 2006 Jan 12;110(1):595-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, in the intermediate stage of ion irradiation, a bcc phase, an amorphous phase, and an order (bcc)-disorder coexisting state appear simultaneously in the Ag12Mo88 multilayered sample and extend over the entire bright field image with unanimously homogeneous composition.
  • In thermodynamic modeling, a Gibbs free energy diagram of the Ag-Mo system is constructed, based on Miedema's model, and suggests that within a narrow composition regime of 85-90 atom % of Mo, the energy difference between the bcc and the amorphous phases is extremely small, which is probably the very reason for the order-disorder coexisting state to appear.
  • The simulations not only determine an intrinsic glass-forming ability/range (GFA/GFR) of the Ag-Mo system to be from 10 to 88 atom % of Mo but also reveal the possibility of the formation/appearance of a crystalline and amorphous mixture in a narrow composition regime of 88-92 atom % of Mo.
  • Apparently, the theoretical results are in excellent agreement and/or compatible with the experimental observations in ion beam mixing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471572.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Panani AD: Isochromosome 5p, a novel recurrent abnormality in breast cancer: is it a common abnormality in cancer? In Vivo; 2010 Sep-Oct;24(5):715-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isochromosome 5p, a novel recurrent abnormality in breast cancer: is it a common abnormality in cancer?
  • BACKGROUND: The detection of recurring genetic changes in breast cancer can be extremely difficult.
  • The tumors display very complex structural chromosomal rearrangements the origin of which are often very difficult to establish.
  • Isochromosome i(5p) is a frequent finding in several types of cancer but it has been rarely described in breast cancer.
  • The aim of the present study was to investigate the presence of i(5p) in primary breast tumors.
  • MATERIALS AND METHODS: Sixteen cases of breast cancer were cytogenetically studied by direct culture of cancerous cells and G-banding technique.
  • We focused on structural aberrations of chromosome 5 in order to identify the presence of i(5p) in breast cancer.
  • RESULTS: All the cases presented complex chromosomal changes with hyperploidization and various unidentified marker chromosomes being the prominent finding.
  • Among 16 cases studied 6 cases presented an i(5p).
  • CONCLUSION: The presence of i(5p) in breast tumors suggests that this chromosomal abnormality plays an important role in the development of breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 5. Isochromosomes

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20952739.001).
  • [ISSN] 1791-7549
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


31. Bowen JL, Crump BC, Deegan LA, Hobbie JE: Salt marsh sediment bacteria: their distribution and response to external nutrient inputs. ISME J; 2009 Aug;3(8):924-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salt marsh sediment bacteria: their distribution and response to external nutrient inputs.
  • A primary focus among microbial ecologists in recent years has been to understand controls on the distribution of microorganisms in various habitats.
  • Much less attention has been paid to the way that environmental disturbance interacts with processes that regulate bacterial community composition.
  • We determined how human disturbance affected the distribution and community structure of salt marsh sediment bacteria by using denaturing gradient gel electrophoresis of 16S rRNA in five different habitats in each of four salt marshes located in northeastern Massachusetts, USA.
  • Two of the four marsh creeks were experimentally enriched 15 x above background by the addition of nitrogen and phosphorus fertilizers for two or more growing seasons.
  • Our results indicate that extrinsic factors acting at broad scales do not influence the distribution of salt marsh sediment bacteria.
  • Intrinsic factors, controlled by local-scale environmental heterogeneity, do play a role in structuring these sediment microbial communities, although nutrient enrichment did not have a consequential effect on the microbial community in most marsh habitats.
  • Only in one habitat, a region of the marsh creek wall that is heavily colonized by filamentous algae, did we see any effect of fertilization on the microbial community structure.
  • When similar habitats were compared among marshes, there was considerable convergence in the microbial community composition during the growing season.
  • Environmental factors that correlated best with microbial community composition varied with habitat, suggesting that habitat-specific intrinsic forces are primarily responsible for maintaining microbial diversity in salt marsh sediments.
  • [MeSH-major] Bacteria / classification. Bacteria / genetics. Biodiversity. Geologic Sediments / microbiology. Wetlands
  • [MeSH-minor] DNA Fingerprinting / methods. DNA, Bacterial / genetics. DNA, Ribosomal / genetics. Electrophoresis, Polyacrylamide Gel / methods. Fertilizers. Humans. Massachusetts. Nitrogen / metabolism. Nucleic Acid Denaturation. Phosphorus / metabolism. RNA, Ribosomal, 16S / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421233.001).
  • [ISSN] 1751-7370
  • [Journal-full-title] The ISME journal
  • [ISO-abbreviation] ISME J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / Fertilizers; 0 / RNA, Ribosomal, 16S; 27YLU75U4W / Phosphorus; N762921K75 / Nitrogen
  •  go-up   go-down


32. Rosner B, Colditz GA, Iglehart JD, Hankinson SE: Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study. Breast Cancer Res; 2008;10(4):R55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study.
  • INTRODUCTION: A number of breast cancer risk prediction models have been developed to provide insight into a woman's individual breast cancer risk.
  • Although circulating levels of estradiol in postmenopausal women predict subsequent breast cancer risk, whether the addition of estradiol levels adds significantly to a model's predictive power has not previously been evaluated.
  • METHODS: Using linear regression, the authors developed an imputed estradiol score using measured estradiol levels (the outcome) and both case status and risk factor data (for example, body mass index) from a nested case-control study conducted within a large prospective cohort study and used multiple imputation methods to develop an overall risk model including both risk factor data from the main cohort and estradiol levels from the nested case-control study.
  • RESULTS: The authors evaluated the addition of imputed estradiol level to the previously published Rosner and Colditz log-incidence model for breast cancer risk prediction within the larger Nurses' Health Study cohort.
  • The follow-up was from 1980 to 2000; during this time, 1,559 invasive estrogen receptor-positive breast cancer cases were confirmed.
  • CONCLUSION: Circulating estradiol levels in postmenopausal women appear to add to other lifestyle factors in predicting a woman's individual risk of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] JAMA. 2001 Nov 7;286(17):2143-51 [11694156.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26 [12928347.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):153-9 [14710223.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 4;96(3):218-28 [14759989.001]
  • [Cites] Stat Med. 2004 Apr 15;23(7):1111-30 [15057881.001]
  • [Cites] Am J Epidemiol. 1984 May;119(5):837-9 [6720679.001]
  • [Cites] Clin Chem. 1989 Dec;35(12):2313-6 [2591049.001]
  • [Cites] Epidemiol Rev. 1993;15(1):48-65 [8405212.001]
  • [Cites] Am J Epidemiol. 1994 Dec 1;140(11):1016-9 [7985649.001]
  • [Cites] J Am Med Womens Assoc. 1995 Mar-Apr;50(2):40-4 [7722205.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1297-302 [7658481.001]
  • [Cites] Cancer Causes Control. 1998 Mar;9(2):199-207 [9578297.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9 [9731736.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8 [10491430.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65 [15601642.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):324-8 [15734953.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):715-23 [15900041.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1071-82 [16322344.001]
  • [Cites] Circulation. 2007 Feb 20;115(7):928-35 [17309939.001]
  • [Cites] Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12 [17569110.001]
  • [Cites] Natl Vital Stat Rep. 2007 Dec 28;56(9):1-39 [18274319.001]
  • [Cites] Biometrics. 2009 Mar;65(1):188-97 [18510654.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46 [10547390.001]
  • [Cites] BMJ. 1999 Dec 11;319(7224):1562-5 [10591726.001]
  • [Cites] Epidemiol Rev. 2000;22(1):176-80 [10939025.001]
  • [Cites] Am J Epidemiol. 2000 Nov 15;152(10):950-64 [11092437.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):47-59 [11227925.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):358-66 [11238697.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):380-3 [12692114.001]
  • (PMID = 18598349.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089393; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / CA49449; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / U01 CA049449
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC2575548
  •  go-up   go-down


33. Ronco AL, De Stefani E, Boffetta P, Deneo-Pellegrini H, Acosta G, Mendilaharsu M: Food patterns and risk of breast cancer: A factor analysis study in Uruguay. Int J Cancer; 2006 Oct 1;119(7):1672-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Food patterns and risk of breast cancer: A factor analysis study in Uruguay.
  • To generate broad eating patterns, which could explain more adequately the breast cancer etiology, we conducted an exploratory factor analysis in Montevideo, Uruguay.
  • The study included 442 newly diagnosed and microscopically confirmed cases with breast cancer and 442 hospitalized controls, with non-neoplastic diseases.
  • After scoring the rotated factors, the relations between scores and breast cancer risk factors were analyzed by using Pearson correlation coefficients.
  • After this step, the odds ratios of breast cancer for continuous scores of the rotated factors were carefully analyzed.
  • Women who reported a history of breast cancer among mother and sisters displayed strong elevations in risk for western (OR 2.03, 95% CI 1.11-3.72) and high-fat (OR 2.72, 95%CI 1.16-6.37) dietary patterns.
  • This finding could suggest that gene-dietary interaction could play an important role in breast carcinogenesis.
  • [MeSH-major] Breast Neoplasms / epidemiology. Diet

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16708380.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Stracci F, La Rosa F, Falsettini E, Ricci E, Aristei C, Bellezza G, Bolis GB, Fenocchio D, Gori S, Rulli A, Mastrandrea V: A population survival model for breast cancer. Breast; 2005 Apr;14(2):94-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population survival model for breast cancer.
  • Breast cancer is a major health problem, and disease control depends on an effective healthcare system.
  • A registry-based tool to monitor the quality of breast cancer care could be useful.
  • The aim of this study was to develop a population survival model for breast cancer based on the Nottingham Prognostic Model (NPM).
  • To this end, 1452 cases of breast cancer diagnosed in the Umbria Region, Italy, during the period 1994-1996 were studied.
  • In about 80% of cases complete information on factors included in the NPM was available.
  • Population survival models based on data from cancer registries may provide a tool that can be used to evaluate healthcare systems and the effectiveness of interventions.
  • [MeSH-major] Breast Neoplasms / mortality. Registries / statistics & numerical data
  • [MeSH-minor] Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Breast. 2005 Apr;14(2):83-4 [15767175.001]
  • (PMID = 15767178.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


35. Dunning K, Gopaldas RR, Rohatgi C: The role of amputation in treating large Basal cell carcinomas of the extremity. Plast Reconstr Surg; 2007 May;119(6):1974-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of amputation in treating large Basal cell carcinomas of the extremity.
  • [MeSH-major] Amputation / methods. Arm / surgery. Carcinoma, Basal Cell / surgery. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged, 80 and over. Axilla. Biopsy, Needle. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis. Quality of Life. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440409.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


36. Peitsch WK, Hofmann I, Bulkescher J, Hergt M, Spring H, Bleyl U, Goerdt S, Franke WW: Drebrin, an actin-binding, cell-type characteristic protein: induction and localization in epithelial skin tumors and cultured keratinocytes. J Invest Dermatol; 2005 Oct;125(4):761-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drebrin, an actin-binding, cell-type characteristic protein: induction and localization in epithelial skin tumors and cultured keratinocytes.
  • Isoform E2 of drebrin, an actin-binding protein originally identified in neuronal cells, has recently been identified in diverse non-neuronal cells, mostly in association with cell processes and intercellular junctions.
  • Here, we report on the presence of drebrin in normal human skin, epithelial skin cancers, and cultured keratinocytes.
  • By immunohistochemistry and immunoblot, basal cell carcinomas (BCC) are rich in drebrin, and confocal laser scanning and immunoelectron microscopy show accumulation at adhering junctions, in co-localization with actin and partially with plaque proteins.
  • In squamous cell carcinomas, keratoacanthomas, and in epidermal precancers, drebrin is heterogeneously distributed, appearing as mosaics.
  • When epithelium-derived cells devoid of drebrin are transfected with drebrin-enhanced green fluorescent protein, constructs accumulate in the cell periphery, and immunoprecipitation shows complexes with actin.
  • During epidermal growth factor induced formation of cell processes, drebrin retains this junction association, as observed by live cell microscopy.
  • Our results suggest novel functions of drebrin such as an involvement in cell-cell adhesion and tumorigenesis and a potential value in diagnosis of BCC.
  • [MeSH-major] Keratinocytes / metabolism. Microfilament Proteins / analysis. Neoplasms, Glandular and Epithelial / chemistry. Neuropeptides / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Female. Fluorescent Antibody Technique. Humans. Immunoblotting. Microscopy, Confocal. Microscopy, Immunoelectron. Skin / chemistry. Transfection

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185277.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Neuropeptides; 0 / drebrin E; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


37. Kara E, Shade A: Temporal dynamics of South End tidal creek (Sapelo Island, Georgia) bacterial communities. Appl Environ Microbiol; 2009 Feb;75(4):1058-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dissolved oxygen concentration and conductivity were important proximate drivers.

  • Hazardous Substances Data Bank. Water .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Ecol Evol. 2006 Sep;21(9):501-7 [16815589.001]
  • [Cites] Environ Microbiol. 2006 Jun;8(6):956-70 [16689717.001]
  • [Cites] Appl Environ Microbiol. 2007 Jan;73(2):659-62 [17122397.001]
  • [Cites] Environ Microbiol. 2007 Jan;9(1):197-205 [17227424.001]
  • [Cites] Nat Rev Microbiol. 2007 May;5(5):384-92 [17435792.001]
  • [Cites] Appl Environ Microbiol. 2007 Nov;73(22):7169-76 [17827330.001]
  • [Cites] ISME J. 2007 May;1(1):38-47 [18043612.001]
  • [Cites] Environ Microbiol. 2008 Apr;10(4):1057-67 [18218031.001]
  • [Cites] Environ Microbiol. 2002 May;4(5):287-95 [12030854.001]
  • [Cites] Int J Syst Evol Microbiol. 2003 Sep;53(Pt 5):1261-9 [13130004.001]
  • [Cites] Microb Ecol. 2003 Nov;46(4):391-405 [12904915.001]
  • [Cites] Appl Environ Microbiol. 2004 Mar;70(3):1658-68 [15006791.001]
  • [Cites] Appl Environ Microbiol. 1999 Jul;65(7):3192-204 [10388721.001]
  • [Cites] Appl Environ Microbiol. 1999 Oct;65(10):4630-6 [10508099.001]
  • [Cites] Appl Environ Microbiol. 2005 Jan;71(1):227-39 [15640192.001]
  • [Cites] Appl Environ Microbiol. 2005 Mar;71(3):1405-16 [15746343.001]
  • [Cites] Environ Microbiol. 2006 May;8(5):929-38 [16623749.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13104-9 [16938845.001]
  • (PMID = 19114517.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 059QF0KO0R / Water; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2643588
  •  go-up   go-down


38. Ghoneum M, Gollapudi S: Synergistic role of arabinoxylan rice bran (MGN-3/Biobran) in S. cerevisiae-induced apoptosis of monolayer breast cancer MCF-7 cells. Anticancer Res; 2005 Nov-Dec;25(6B):4187-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic role of arabinoxylan rice bran (MGN-3/Biobran) in S. cerevisiae-induced apoptosis of monolayer breast cancer MCF-7 cells.
  • We have recently demonstrated that breast cancer cell (BCC) lines undergo apoptosis following phagocytosis of S. cerevisiae.
  • Since previous data were obtained using cells in suspension, the present study was undertaken to examine monolayer BCC that more closely model cancer cell growth.
  • Monolayers of both breast cancer (MCF-7) and non-tumorgenic breast epithelial (MCF-10A) cells grown on glass coverslips were cultured with heat-killed S. cerevisiae at a ratio of 1:10, respectively.
  • These data may have implications in the treatment of breast cancer.
  • [MeSH-major] Apoptosis / drug effects. Breast Neoplasms / therapy. Probiotics / pharmacology. Saccharomyces cerevisiae / physiology. Xylans / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Drug Synergism. Humans. Phagocytosis / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309215.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Xylans; 0 / polysaccharide MGN3
  •  go-up   go-down


39. Hirsch AE, Atencio DP, Rosenstein BS: Screening for ATM sequence alterations in African-American women diagnosed with breast cancer. Breast Cancer Res Treat; 2008 Jan;107(1):139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.
  • BACKGROUND: Women who are heterozygous for variants in the ataxia telangiectasia mutated (ATM) gene, ATM carriers, have been reported to be at increased risk for breast cancer compared with women who do not posses an alteration in this gene.
  • Aside from BRCA1 and BRCA2, there are few data on breast cancer susceptibility genes in African-American women.
  • The goal of this study was to determine whether there is evidence that ATM is a breast cancer susceptibility gene in African-American women.
  • Thirty-seven (28%) were women with a histological diagnosis of breast cancer (cases).
  • These women were not selected on the basis of a breast cancer family history.
  • Ninety-five (72%) were age-matched women who had not been diagnosed with breast cancer (controls).
  • RESULTS: Twenty-three of the 37 (62%) cases possessed at least one ATM variant.
  • For subjects specifically possessing missense variants, 46% of cases and 48% of controls had these types of sequence variants.
  • In addition, 19% of cases and 34% of controls possessed multiple ATM sequence variants (P = 0.07).
  • The most common polymorphisms were the 378 T --> A which was seen in 19% of cases and 27% of controls (P = 0.22), 5557 G --> A identified in 22% of cases and 18% of controls (p = 0.40), 2685 A --> G which was detected in 11% of cases and 6% of controls (P = 0.22), and 1254 A --> G which was found in 3% of cases and 9% of controls (P = 0.36).
  • Hence, there were no significant differences in any of the genetic variants detected between the case and control subjects.
  • CONCLUSION: We found no statistically significant differences in the overall frequency of ATM variants, nor any specific variant type or group, between African-American women who had been diagnosed with breast cancer compared with an age-matched cohort of African-American women who did not have breast cancer.
  • ATM, therefore, does not appear to represent a breast cancer susceptibility gene in the general African-American population.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Cell Cycle Proteins / genetics. Cell Cycle Proteins / physiology. DNA-Binding Proteins / genetics. DNA-Binding Proteins / physiology. Protein-Serine-Threonine Kinases / genetics. Protein-Serine-Threonine Kinases / physiology. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] African Americans. Aged. Ataxia Telangiectasia Mutated Proteins. Case-Control Studies. Cohort Studies. Female. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease. Humans. Mass Screening. Middle Aged. Mutation, Missense. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333338.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


40. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.
  • All have met with a fair amount of success in controlling local disease; however, the number of patients treated in each instance is small, making it difficult to design an evidence-based treatment strategy.
  • Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


41. Weaver J, Billings SD: Initial presentation of stasis dermatitis mimicking solitary lesions: a previously unrecognized clinical scenario. J Am Acad Dermatol; 2009 Dec;61(6):1028-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Stasis dermatitis is a common skin condition secondary to chronic venous insufficiency.
  • Characteristic dermatologic changes in well-developed disease include bilateral erythematous, scaly, and slightly discolored papules and plaques on the lower legs.
  • Early recognition of signs and appropriate diagnosis can lead to timely treatment that can prevent painful complications, such as leg ulcers which are at risk for development of squamous cell carcinoma.
  • METHODS: Thirty-seven cases of stasis dermatitis submitted with the clinical diagnosis of a solitary lesion were identified.
  • All cases of stasis dermatitis presenting for the first time as a solitary lesion were reviewed retrospectively both clinically and pathologically.
  • RESULTS: Squamous cell carcinoma was most commonly suspected (33%), followed by basal cell carcinoma (24%), and a variety of other solitary lesions.
  • The histopathology was characteristic of stasis dermatitis in all cases with absent or mild spongiosis (82%), variable acanthosis and dermal fibrosis, and proliferation of papillary dermal thick-walled vessels were prominent (2-3+) in nearly all cases (>or=90%) along with hemosiderin-laden macrophages and extravasated red blood cells (>or=95%).
  • LIMITATIONS: The study is limited by its retrospective nature and absence of clinical images on all cases.
  • CONCLUSION: Stasis dermatitis may present as a solitary lesion mimicking a neoplasm.
  • [MeSH-major] Leg Dermatoses / diagnosis. Skin Neoplasms / diagnosis. Venous Insufficiency / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925928.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Essers BA, Dirksen CD, Nieman FH, Smeets NW, Krekels GA, Prins MH, Neumann HA: Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol; 2006 Feb;142(2):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face.
  • OBJECTIVE: To assess the cost-effectiveness of Mohs micrographic surgery (MMS) compared with the surgical excision for both primary and recurrent basal cell carcinoma (BCC).
  • PARTICIPANTS: A total of 408 primary (374 patients) and 204 recurrent (191 patients) cases of facial BCC were included.
  • MAIN OUTCOME MEASURES: The mean total treatment costs of MMS and surgical excision for both primary and recurrent BCC and the incremental cost-effectiveness ratio, calculated as the difference in costs between MMS and surgical excision divided by their difference in effectiveness.
  • RESULTS: Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).
  • For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.
  • CONCLUSIONS: At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.
  • However, because a 5-year period is normally required to determine definite recurrence rates, it is possible that MMS may become a cost-effective treatment for recurrent BCC.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Facial Neoplasms / economics. Mohs Surgery / economics
  • [MeSH-minor] Aged. Cost-Benefit Analysis. Female. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Netherlands. Prospective Studies. Quality of Life. Treatment Outcome

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Feb;142(2):231-2 [16490852.001]
  • [CommentIn] Arch Dermatol. 2006 Sep;142(9):1235; author reply 1235-6 [16983019.001]
  • (PMID = 16490846.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Kovarik CL, Stewart D, Barnard JJ: Lethal basal cell carcinoma secondary to cerebral invasion. J Am Acad Dermatol; 2005 Jan;52(1):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal basal cell carcinoma secondary to cerebral invasion.
  • Intracranial invasion by a basal cell carcinoma on the scalp is extremely rare.
  • We present an autopsy case of a 57-year-old woman who developed a large destructive basal cell carcinoma with extension through the calvarium and compression of the dura.
  • We compare 7 similar cases reported in the literature and review the risks for development of these aggressive fatal basal cell carcinomas on the scalp.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Autopsy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627099.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


44. Lindelöf B: [Basal cell cancer should primarily be treated surgically. There are a lot of alternative therapeutic methods but few comparative studies]. Lakartidningen; 2005 May 23-29;102(21):1650-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell cancer should primarily be treated surgically. There are a lot of alternative therapeutic methods but few comparative studies].
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962888.001).
  • [ISSN] 0023-7205
  • [Journal-full-title] Läkartidningen
  • [ISO-abbreviation] Lakartidningen
  • [Language] swe
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


45. Tirona MT, Sehgal R, Ballester O: Prevention of breast cancer (part I): epidemiology, risk factors, and risk assessment tools. Cancer Invest; 2010 Aug;28(7):743-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of breast cancer (part I): epidemiology, risk factors, and risk assessment tools.
  • Advances in breast cancer research have led to declining death rates from this disease because of early detection through mammographic screening and improved therapy for breast cancer.
  • The concept that breast cancer, in some cases, can be prevented has been explored over the last three decades.
  • This article, part I of a two-part series, will focus on the epidemiology, the risk factors associated with breast cancer, and the available risk assessment tools, which can help define who should be considered for risk reduction strategies.
  • [MeSH-major] Breast Neoplasms / epidemiology. Risk Assessment / methods
  • [MeSH-minor] Aged. Breast Neoplasms, Male / epidemiology. Continental Population Groups. Family Health. Female. Hormone Replacement Therapy / adverse effects. Humans. Male. Middle Aged. Nutritional Status. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20636109.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Rukin NJ, Zeegers MP, Ramachandran S, Luscombe CJ, Liu S, Saxby M, Lear J, Strange RC: A comparison of sunlight exposure in men with prostate cancer and basal cell carcinoma. Br J Cancer; 2007 Feb 12;96(3):523-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of sunlight exposure in men with prostate cancer and basal cell carcinoma.
  • Ultraviolet radiation exposure increases basal cell carcinoma (BCC) risk, but may be protective against prostate cancer.
  • We attempted to identify exposure patterns that confer reduced prostate cancer risk without increasing that of BCC.
  • We used a questionnaire to assess exposure in 528 prostate cancer patients and 442 men with basal cell carcinoma, using 365 benign prostatic hypertrophy patients as controls.
  • Skin type 1 (odds ratio (OR)=0.47, 95% CI=0.26-0.86), childhood sunburning (OR=0.38, 95% CI=0.26-0.57), occasional/frequent sunbathing (OR=0.21, 95% CI=0.14-0.31), lifetime weekday (OR=0.85, 95% CI=0.80-0.91) and weekend exposure (OR=0.79, 95% CI=0.73-0.86) were associated with reduced prostate cancer risk.
  • Skin type 1 (OR=4.00, 95% CI=2.16-7.41), childhood sunburning (OR=1.91, 95% CI=1.36-2.68), regular foreign holidays (OR=6.91, 95% CI=5.00-9.55) and weekend (OR=1.17, 95% CI=1.08-1.27) but not weekday exposure were linked with increased BCC risk.
  • Combinations of one or two parameters were associated with a progressive decrease in the ORs for prostate cancer risk (OR=0.54-0.25) with correspondingly increased BCC risk (OR=1.60-2.54).
  • Our data do not define exposure patterns that reduce prostate cancer risk without increasing BCC risk.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Prostatic Neoplasms / etiology. Sunlight / adverse effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2002 Apr;31(2):439-46 [11980813.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1867-75 [11920550.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):145-9 [12668278.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):104-8 [14618623.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):549-52 [15225836.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):965-72 [15482486.001]
  • [Cites] J Invest Dermatol. 1981 Jul;77(1):154-7 [7252250.001]
  • [Cites] J Urol. 1984 Sep;132(3):474-9 [6206240.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2861-9 [1451068.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):489-94 [7829262.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):857-63 [9796629.001]
  • [Cites] J Nutr. 2005 Feb;135(2):310-6 [15671233.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):468-73 [15761425.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5470-9 [15958597.001]
  • [Cites] Am J Epidemiol. 2005 Jul 15;162(2):183-92 [15972935.001]
  • [Cites] Semin Dial. 2005 Jul-Aug;18(4):276-89 [16076349.001]
  • [Cites] Peptides. 2005 Oct;26(10):1965-71 [15963603.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2739S-48S [16251641.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):184-94 [16678047.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):9-16 [16603232.001]
  • [Cites] Bull World Health Organ. 2006 Jun;84(6):485-91 [16799733.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1538-44 [16896046.001]
  • [Cites] BJU Int. 2000 Jun;85(9):1037-48 [10848691.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Lancet. 2001 Aug 25;358(9282):641-2 [11530156.001]
  • [Cites] Arch Dermatol. 2001 Sep;137(9):1162-8 [11559211.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1494-7 [12437456.001]
  • (PMID = 17262085.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360028
  •  go-up   go-down


47. Talpur R, Cox K, Duvic M: Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol; 2009 Feb;5(2):195-210
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders.
  • Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer.
  • [MeSH-minor] Administration, Cutaneous. Animals. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Humans. Receptors, Retinoic Acid / drug effects. Receptors, Retinoic Acid / genetics. Skin Aging / drug effects. Up-Regulation / drug effects

  • MedlinePlus Health Information. consumer health - Acne.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213916.001).
  • [ISSN] 1744-7607
  • [Journal-full-title] Expert opinion on drug metabolism & toxicology
  • [ISO-abbreviation] Expert Opin Drug Metab Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Nicotinic Acids; 0 / RARRES3 protein, human; 0 / Receptors, Retinoic Acid; 81BDR9Y8PS / tazarotene
  • [Number-of-references] 118
  •  go-up   go-down


48. Ruiz-Villaverde R, Sánchez-Cano D, Burkhardt-Pérez P: Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series. J Eur Acad Dermatol Venereol; 2009 Jul;23(7):828-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
  • Basal cell carcinoma (BCC) is a malignant cutaneous neoplasm with a tendency to spread locally and with several clinical and histological subsets.
  • We studied 82 patients with a clinical diagnosis of superficial BCC on different anatomical locations, to whom imiquimod 5% cream was administered on a low-frequency regime (three times a week for 4 weeks), and who were followed up 2 years after completion of treatment.
  • We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of superficial BCC in patients with associated comorbidities.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646136.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


49. Osaka N, Shibayama M: Pressure-induced phase transitions of hydrophobically solvated block-copolymer solutions. Phys Rev Lett; 2006 Feb 3;96(4):048303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At ambient pressure, the solution underwent a two-step transition at 40 and 65 degrees C, both of which were convex-upward functions of P having a maximum around P0 approximately 150 MPa.
  • The first transition was assigned to a microphase separation to form a bcc structure, and the second was to a macrophase separation.

  • Hazardous Substances Data Bank. Water .
  • Hazardous Substances Data Bank. DEUTERIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16486903.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ethers; 0 / Polyvinyls; 0 / Solutions; 0 / poly(2-(2-ethoxy)ethoxyethyl vinyl ether)-block-poly(2-methoxyethyl vinyl ether); 059QF0KO0R / Water; AR09D82C7G / Deuterium
  •  go-up   go-down


50. Thongtan J, Saenboonrueng J, Rachtawee P, Isaka M: An antimalarial tetrapeptide from the entomopathogenic fungus Hirsutella sp. BCC 1528. J Nat Prod; 2006 Apr;69(4):713-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An antimalarial tetrapeptide from the entomopathogenic fungus Hirsutella sp. BCC 1528.
  • Hirsutellic acid A (1), a new linear tetrapeptide possessing an anthranilic acid residue at the C-terminus, was isolated from a fermentation broth of the entomopathogenic fungus Hirsutella sp. BCC 1528.
  • Hirsutellic acid A exhibits activity against the malarial parasite Plasmodium falciparum K1 with an IC(50) value of 8.0 microM, while it was noncytotoxic to Vero cells at a concentration of 95 microM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643062.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Oligopeptides; 0 / hirsutellic acid A
  •  go-up   go-down


51. Oakman C, Viale G, Di Leo A: Management of triple negative breast cancer. Breast; 2010 Oct;19(5):312-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of triple negative breast cancer.
  • Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases.
  • In a minority of patients with highly chemosensitive disease, no robust clinical evidence exists to guide use of current cytotoxics.
  • Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Triple Negative Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Ixabepilone .
  • Hazardous Substances Data Bank. PLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20382530.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Epothilones; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Taxoids; 49DFR088MY / Platinum; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; K27005NP0A / ixabepilone
  •  go-up   go-down


52. Werkoff G, Morel O, Malartic C, Desfeux P, Akerman G, Tulpin L, Barranger E: [Pregnancy after breast cancer: the obstetrician's point of view. Literature review]. Gynecol Obstet Fertil; 2008 Oct;36(10):1022-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pregnancy after breast cancer: the obstetrician's point of view. Literature review].
  • [Transliterated title] Grossesse après cancer du sein : le point de vue de l'obstétricien. Revue de la littérature.
  • In 10 to 15% of cases, breast cancer occurs in women under the age of 40.
  • Thanks to the development of novel therapeutic approaches in the past few years, breast cancer prognosis is today far more acute than before and a pregnancy can be planned in these young women.
  • They are expecting from their physician clear information about possibilities for pregnancy and specific risks after breast cancer.
  • Several questions are raised in such situations: Does pregnancy modifies breast cancer prognosis?
  • What is the influence of breast cancer for pregnancy?
  • How do these young patients experience pregnancy and breast cancer?
  • The goal of this paper, based upon literature review, was to clarify guidelines for the follow-up of young women experiencing pregnancy after breast cancer.
  • [MeSH-major] Breast Neoplasms / complications. Patient Education as Topic. Pregnancy / physiology. Risk Assessment
  • [MeSH-minor] Adult. Breast Feeding. Female. Humans. Neoplasm Recurrence, Local. Pregnancy Outcome. Prognosis. Risk Factors


53. Arad S, Zattra E, Hebert J, Epstein EH Jr, Goukassian DA, Gilchrest BA: Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice. Am J Pathol; 2008 May;172(5):1248-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice.
  • Treatment with thymidine dinucleotide (pTT) has well documented DNA-protective effects and reduces development of squamous cell carcinoma in UV-irradiated mice.
  • The preventive effect of pTT on basal cell carcinoma (BCC) was evaluated in UV-irradiated Ptch-1(+/-) mice, a model of the human disease Gorlin syndrome.
  • Topical pTT treatment significantly reduced the number and size (P < 0.001) of BCCs in murine skin after 7 months of chronic irradiation.
  • Skin biopsies collected 24 hours after the final UV exposure showed that pTT reduced the number of nuclei positive for cyclobutane pyrimidine dimers by 40% (P < 0.0002) and for 8-hydroxy-2'-deoxyguanosine by 61% (P < 0.01 compared with vehicle control).
  • Immunostaining with an antibody specific for mutated p53 revealed 63% fewer positive patches in BCCs of pTT-treated mice compared with controls (P < 0.01), and the number of Ki-67-positive cells was decreased by 56% (P < 0.01) in pTT-treated tumor-free epidermis and by 76% (P < 0.001) in BCC tumor nests (P < 0.001).
  • Terminal dUTP nick-end labeling staining revealed a 213% increase (P < 0.04) in the number of apoptotic cells in BCCs of pTT-treated mice.
  • We conclude that topical pTT treatment during a prolonged period of intermittent UV exposure decreases the number and size of UV-induced BCCs through several anti-cancer mechanisms.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 2;280(4):1042-7 [11162632.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):293-7 [11174390.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5532-40 [11574485.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] FASEB J. 2002 May;16(7):754-6 [11923222.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] Australas J Dermatol. 2002 Nov;43(4):241-6 [12423429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):527-31 [12515865.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3933-8 [14999099.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4385-9 [15231643.001]
  • [Cites] FASEB J. 2004 Sep;18(12):1373-81 [15333580.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1614-8 [8434025.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4756-9 [8062275.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):413-4 [7984233.001]
  • [Cites] Science. 1994 Dec 23;266(5193):1954-6 [7801120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):274-8 [8552621.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1087-92 [8577719.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 20;88(6):349-54 [8609643.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12627-32 [9356500.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] J Invest Dermatol. 1999 Jan;112(1):25-31 [9886259.001]
  • [Cites] Science. 1999 Feb 26;283(5406):1321-5 [10037601.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10911-5 [10196169.001]
  • [Cites] Cell. 1999 May 14;97(4):503-14 [10338214.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2006-11 [15598755.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Mar;19(2):180-6 [15752287.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6006-10 [16024598.001]
  • [Cites] J Biol Chem. 2005 Sep 16;280(37):32379-88 [16046401.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Nov;10(2):124-30 [16363064.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):1143-51 [16528365.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):92-6 [16616325.001]
  • [Cites] FASEB J. 2006 Sep;20(11):1895-7 [16877521.001]
  • [Cites] J Cell Physiol. 2007 Mar;210(3):582-95 [17133364.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):435-40 [10951280.001]
  • [Cites] DNA Repair (Amst). 2007 Apr 1;6(4):544-59 [17112792.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R13 [17257427.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2918-30 [17449721.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Nov 1;224(3):257-64 [17276471.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • (PMID = 18403589.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 10515; United States / NCI NIH HHS / CA / R01 CA109584; United States / NIAMS NIH HHS / AR / AR 050440; United States / NIAMS NIH HHS / AR / P01 AR050440; United States / NCI NIH HHS / CA / CA 109584
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Pyrimidine Dimers; 0 / Receptors, Cell Surface; 0 / Thymine Nucleotides; 0 / patched receptors; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ PMC2329834
  •  go-up   go-down


54. Schwarz-Furlan S, Brase C, Stockmann P, Furlan I, Hartmann A: [Hereditary head and neck tumors]. Pathologe; 2010 Oct;31(6):477-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The corresponding genetic defects of the mitochondrial succinate dehydrogenase complex induce autonomous tumor cell growth.
  • In patients with Gorlin-Goltz syndrome basal cell carcinomas and keratocystic odontogenic tumors usually occur much earlier than in patients with sporadic tumors.
  • The associated germline mutations are located in the patched gene which is a modulator of the cell cycle.
  • Fanconi anemia represents a chromosomal instability syndrome which is characterized by early onset of pancytopenia, i.e. bone marrow failure and subsequent development of acute myeloid leukemia and/or squamous cell carcinomas, especially of the head and neck.
  • [MeSH-minor] Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. DNA Repair. DNA, Neoplasm / genetics. Eye Enucleation. Fanconi Anemia / genetics. Fanconi Anemia / pathology. Genomic Instability. Humans. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Paraganglioma / genetics. Paraganglioma / pathology. Radiography

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2003 Jan;72(1):216-8 [12549483.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4223-33 [16493006.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):965-78 [16857415.001]
  • [Cites] BMC Biochem. 2007 Nov 22;8 Suppl 1:S10 [18047734.001]
  • [Cites] Orphanet J Rare Dis. 2008 Nov 25;3:32 [19032739.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1272-84 [18684026.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1976 Jul;42(1):54-72 [1065842.001]
  • [Cites] Hum Pathol. 1976 Jul;7(4):361-73 [939535.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 16;88(20):1489-91 [8841025.001]
  • [Cites] Annu Rev Genet. 2009;43:223-49 [19686080.001]
  • [Cites] J Laryngol Otol. 1999 Aug;113(8):779-83 [10748863.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Head Neck. 2005 Sep;27(9):825-8 [15920750.001]
  • [Cites] HNO. 2004 Jun;52(6):569-74; quiz 575 [15241514.001]
  • [Cites] Arch Pathol Lab Med. 1999 Nov;123(11):1118-20 [10539921.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5210-6 [11701678.001]
  • [Cites] J Cutan Pathol. 1985 Feb;12(1):72-9 [2982934.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] J Med Genet. 2005 Nov;42(11):811-9 [16272260.001]
  • [Cites] J Cutan Pathol. 1997 Aug;24(7):449-53 [9274965.001]
  • [Cites] N Engl J Med. 2010 May 20;362(20):1909-19 [20484397.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):1938-44 [19336503.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] J Med Genet. 2002 Sep;39(9):617-22 [12205103.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):764-71 [19576851.001]
  • [Cites] Int J Oral Maxillofac Surg. 1999 Jun;28(3):216-23 [10355946.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Am J Med Genet A. 2005 Jan 30;132A(3):324-8 [15690381.001]
  • [Cites] Q J Med. 1987 Sep;64(245):769-82 [2897130.001]
  • [Cites] Hum Mutat. 2009 Jul;30(7):1025-36 [19462465.001]
  • [Cites] Clin Genet. 2006 Sep;70(3):246-9 [16922728.001]
  • [Cites] J Med Genet. 2008 Nov;45(11):689-94 [18978332.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • (PMID = 20844882.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


55. Kaae J, Philipsen PA, Haedersdal M, Wulf HC: Immediate whealing urticaria in red light exposed areas during photodynamic therapy. Acta Derm Venereol; 2008;88(5):480-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the recommended first-line treatments for basal cell carcinomas, actinic keratoses and Bowen's disease is photodynamic therapy.

  • MedlinePlus Health Information. consumer health - Hives.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779886.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Histamine Antagonists; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


56. Mamelak AJ, Wang SQ, Goldberg LH: Linear closure for nasal defects after Mohs micrographic surgery. J Drugs Dermatol; 2009 Jan;8(1):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Skin cancers on the nose are very common.
  • METHODS: A retrospective analysis was conducted of 4765 patients with skin malignancies on the nose that were treated with MMS between July 1997 and January 2006.
  • The 2 major malignancies treated were basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Nose Neoplasms / surgery. Prospective Studies. Retrospective Studies. Skin Transplantation. Surgical Flaps. Young Adult

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180892.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Ahlgrimm-Siess V, Cao T, Oliviero M, Hofmann-Wellenhof R, Rabinovitz HS, Scope A: The vasculature of nonmelanocytic skin tumors in reflectance confocal microscopy: vascular features of basal cell carcinoma. Arch Dermatol; 2010 Mar;146(3):353-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The vasculature of nonmelanocytic skin tumors in reflectance confocal microscopy: vascular features of basal cell carcinoma.
  • [MeSH-major] Blood Vessels / pathology. Carcinoma, Basal Cell / blood supply. Dermoscopy / methods. Microscopy, Confocal / methods. Skin Neoplasms / blood supply
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231518.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Thakur S, Chalioulias K, Hayes M, While A: Bilateral primary Merkel cell carcinoma of the upper lid misdiagnosed as Basal cell carcinoma. Orbit; 2008;27(2):139-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral primary Merkel cell carcinoma of the upper lid misdiagnosed as Basal cell carcinoma.
  • Merkel cell tumour is a rare primary malignant tumour of the skin that can affect the lids and periocular region.
  • Clinically, it is difficult to distinguish from other malignancies and the diagnosis requires careful histological analysis and immunocytochemical staining.
  • A case of Merkel cell tumour affecting the lids and originally misdiagnosed is presented.
  • Correct diagnosis was made only after the appearance of a second Merkel cell tumour on the contralateral lid.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Eyelid Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Diagnostic Errors. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415877.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS: Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther; 2009 May;8(10):907-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues.
  • The Cub and Sushi Multiple Domains-1 (CSMD1) is a tumor suppressor gene on 8p23.2, where allelic loss is both frequent and associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC).
  • To understand the extent of CSMD1 aberrations in vivo, we characterized 184 primary tumors from the head and neck, lung, breast and skin for gene copy number and analyzed expression in our HNSCCs and lung squamous cell carcinomas (SCCs).
  • We detected loss of CSMD1 in a large proportion of HNSCCs (50%), lung (46%) and breast cancers (55%), and to a lesser extent in cutaneous SCCs (29%) and basal cell carcinomas (BCCs, 17%) using array-based comparative genomic hybridization (aCGH).
  • CSMD1 expression was decreased in tumors compared to adjacent benign tissue (65%, 13/20) and was likely due to gene loss in 45% of cases (9/20).
  • We show loss of CSMD1 in primary HNSCC tissues, and document for the first time that CSMD1 is lost in breast, lung and cutaneous SCCs.
  • [MeSH-major] Breast Neoplasms / genetics. Head and Neck Neoplasms / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Chromosome Deletion. Comparative Genomic Hybridization. DNA, Neoplasm / analysis. Female. Gene Dosage. Gene Expression. Humans. Loss of Heterozygosity. Mouth Neoplasms / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism


60. Agero AL, Busam KJ, Benvenuto-Andrade C, Scope A, Gill M, Marghoob AA, González S, Halpern AC: Reflectance confocal microscopy of pigmented basal cell carcinoma. J Am Acad Dermatol; 2006 Apr;54(4):638-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reflectance confocal microscopy of pigmented basal cell carcinoma.
  • BACKGROUND: Reflectance confocal microscopy (RCM) is a high-resolution imaging tool for in vivo noninvasive evaluation of skin lesions.
  • OBJECTIVE: We sought to describe the relevant RCM features for pigmented basal cell carcinoma (BCC).
  • METHODS: Pigmented skin lesions with a differential diagnosis of pigmented BCC were imaged using dermoscopy and RCM, followed by excision for histologic analysis.
  • LIMITATIONS: The pigmented BCCs imaged in this study were predominantly nodular; a different set or additional criteria may be necessary for detection of infiltrative and metatypical BCCs.
  • CONCLUSION: RCM may permit in vivo diagnosis of pigmented BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Melanoma / diagnosis. Melanoma / pathology. Microscopy, Confocal. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546585.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Raaby L, Otkjær K, Salvskov-Iversen ML, Johansen C, Iversen L: A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. Dermatol Reports; 2010 Aug 31;2(2):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis.
  • 14-3-3 is a highly conserved protein involved in a number of cellular processes including cell signalling, cell cycle regulation and gene transcription.
  • The expression profile of the various isoforms in skin diseases is unknown.
  • To investigate the expression of the seven 14-3-3 isoforms in involved and uninvolved skin from psoriasis, basal cell carcinoma (BCC), atopic dermatitis and nickel induced allergic contact dermatitis.
  • Punch biopsies from involved and uninvolved skin were analyzed with quantitative reverse transcription-polymerase chain reaction to determine the mRNA expression of the 14-3-3 isoforms.
  • Increased 14-3-3τ mRNA levels were detected in involved skin from patients with psoriasis, contact dermatitis and BCC.
  • 14-3-3σ mRNA expression was increased in psoriasis and contact dermatitis, but not in BCC.
  • In atopic dermatitis no significant difference between involved and uninvolved skin was found.
  • Only 14-3-3τ expression was significantly increased in involved psoriatic skin compared with uninvolved skin.
  • Immunofluorescence staining with 14-3-3τ- and 14-3-3σ-specific antibodies showed localization of both isoforms to the cytoplasm of the keratinocytes in the various skin sections.
  • These results demonstrate a disease specific expression profile of the 14-3-3τ and 14-3-3σ iso-forms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386251.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211473
  • [Keywords] NOTNLM ; 14-3-3 proteins / allergic contact dermatitis / atopic dermatitis. / basal cell carcinoma / psoriasis
  •  go-up   go-down


62. Abraham G, Kowalczyk A, Loi S, Haviv I, Zobel J: Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics; 2010;11:277
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context.
  • BACKGROUND: Different microarray studies have compiled gene lists for predicting outcomes of a range of treatments and diseases.
  • We classified breast cancer cases from five microarray studies according to the risk of metastasis, using features derived from predefined gene sets.
  • In addition, we performed this analysis in each breast cancer molecular subtype, based on ER/HER2 status.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Gene Expression Profiling / methods


63. Guo P, Wang X, Zhu W, Yang H, Cheng X, Cui Z: Degradation of corn stalk by the composite microbial system of MC1. J Environ Sci (China); 2008;20(1):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Degradation of corn stalk by the composite microbial system of MC1.
  • The composite microbial system of MC1 was used to degrade corn stalk in order to determine properties of the degraded products as well as bacterial composition of MC1.
  • Results indicated that the pH of the fermentation broth was typical of lignocellulose degradation by MC1, decreasing in the early phase and increasing in later stages of the degradation.
  • The microbial biomass peaked on the day 3 after degradation.
  • The MC1 efficiently degraded the corn stalk by nearly 70% during which its cellulose content decreased by 71.2%, hemicellulose by 76.5% and lignin by 24.6%.
  • The content of water-soluble carbohydrates (WSC) in the fermentation broth increased progressively during the first three days, and decreased thereafter, suggesting an accumulation of WSC in the early phase of the degradation process.
  • Total levels of various volatile products peaked in the third day after degradation, and 7 types of volatile products were detected in the fermentation broth.
  • These were ethanol, acetic acid, 1,2-ethanediol, propanoic acid, butanoic acid, 3-methyl-butanoic acid and glycerine.
  • Six major compounds were quantitatively analysed and the contents of each compound were ethanol (0.584 g/L), acetic acid (0.735 g/L), 1,2-ethanediol (0.772 g/L), propanoic acid (0.026 g/L), butanoic acid (0.018 g/L) and glycerine (4.203 g/L).
  • Characterization of bacterial cells collected from the culture solution, based on 16S rDNA PCR-DGGE analysis of DNAs, showed that the composition of bacterial community in MC1 coincided basically with observations from previous studies.
  • This indicated that the structure of MC1 is very stable during degradation of different lignocellulose materials.
  • [MeSH-major] Bacteria / metabolism. Zea mays / metabolism
  • [MeSH-minor] Cellulose / metabolism. DNA, Bacterial / genetics. DNA, Ribosomal / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18572532.001).
  • [ISSN] 1001-0742
  • [Journal-full-title] Journal of environmental sciences (China)
  • [ISO-abbreviation] J Environ Sci (China)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 9004-34-6 / Cellulose
  •  go-up   go-down


64. Plevová P, Bouchal J, Fiurásková M, Foretová L, Navrátilová M, Zapletalová J, Curík R, Kubala O, Prokop J, Kolár Z: PML protein expression in hereditary and sporadic breast cancer. Neoplasma; 2007;54(4):263-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PML protein expression in hereditary and sporadic breast cancer.
  • Downregulation of the PML protein has been described in various types of cancer and is in accordance with the fact that dysqualification of tumor suppressive functions of the PML protein might promote cancer development.
  • Various differences have been described between sporadic breast cancer and that associated with BRCA1 and BRCA2 gene mutations.
  • The aim of this study was to determine if there is any difference in PML protein expression in breast cancer of BRCA1 and BRCA2 gene mutation carriers compared to sporadic breast cancer and if the PML protein can be used as a prognostic marker.
  • There were 47 breast cancer samples included, 14 and 10 from BRCA1 and BRCA2 germline mutation carriers, respectively, and 23 from patients without a BRCA1/BRCA2 germline mutation.
  • Downregulation of PML protein expression was found in 2 of 14 (14%), 3 of 10 (30%) and 15 of 47 (31%) cases of breast cancer samples from BRCA1, BRCA2 and no BRCA1/BRCA2 mutation carriers, respectively (p(BRCA1) = 0.019; p(BRCA2) = 0.111).
  • There was no correlation between PML protein expression and age, histological types, estrogen and progesterone receptor, c-erbB-2 and PCNA expression, TNM classification, disease-free and overall survival.
  • In conclusion, the PML protein is downregulated in approximately 30% of breast cancers cases.
  • Downregulation of PML protein expression was significantly less frequent in BRCA1 mutation carriers compared to sporadic cases.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Germ-Line Mutation / genetics. Neoplasm Proteins / metabolism. Nuclear Proteins / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. BRCA1 Protein / genetics. BRCA2 Protein / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Fluorescent Antibody Technique, Indirect. Heterozygote. Humans. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Zinc Fingers


65. Takata Y, Maskarinec G, Le Marchand L: Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the Multiethnic Cohort. BMC Cancer; 2007 Feb 12;7:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the Multiethnic Cohort.
  • BACKGROUND: Mammographic density is a strong predictor of breast cancer risk and is increased by hormone replacement therapy (HRT).
  • This cross-sectional analysis examined the relation between mammographic density and the CYP1A2*1F and COMT Val58 Met polymorphisms among 332 breast cancer cases and 254 controls in the Hawaii component of the Multiethnic Cohort.
  • METHODS: Mammographic density, before diagnosis in cases, was quantified by using a validated computer-assisted method.
  • RESULTS: A positive association between the C allele in the CYP1A2*1F gene and percent density, but not the dense area, was suggested (p = 0.11).
  • We did not observe any relation between the COMT Val58 Met polymorphism and breast density.
  • CONCLUSION: The lack of an association between the CYP1A2 genotype and the size of the dense areas suggests an effect on the non-dense, i.e., fatty breast tissue.
  • The discrepancies among studies may be due to differential susceptibility; changes in enzyme activity as a result of the CYP1A2*1F polymorphism may influence breast tissue differently depending on hormonal status.
  • Larger studies with the ability to look at interactions would be useful to elucidate the influence of genetic variation in CYP1A2 and COMT on the risk of developing breast cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Clin Pharmacol. 1999 Apr;47(4):445-9 [10233211.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1133-44 [9865433.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2049-58 [15900297.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1521-7 [15941966.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R336-44 [15987428.001]
  • [Cites] Med Hypotheses. 2005;65(4):760-5 [15961252.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1998-2003 [16103451.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):115-24 [16112414.001]
  • [Cites] Am J Epidemiol. 2005 Oct 15;162(8):743-52 [16150892.001]
  • [Cites] Am J Epidemiol. 2005 Nov 1;162(9):826-34 [16177147.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2641-7 [16284390.001]
  • [Cites] Eur J Clin Pharmacol. 2006 Jan;62(1):23-8 [16385402.001]
  • [Cites] Breast. 2006 Feb;15(1):20-8 [16000251.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):551-8 [16537715.001]
  • [Cites] Pharmacogenet Genomics. 2006 Apr;16(4):237-43 [16538170.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1502-8 [16896040.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Oct;65(4):506-13 [16984244.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):843-54 [10548311.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):1023-32 [10566559.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R5 [12052257.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):876-82 [12373602.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):30-7 [12509398.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jan;77(1):27-36 [12602902.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26 [12928347.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):838-47 [14504192.001]
  • [Cites] Breast Cancer Res. 2004;6(4):R338-51 [15217501.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):683-8 [15382051.001]
  • [Cites] Obes Rev. 2004 Nov;5(4):197-216 [15458395.001]
  • [Cites] Radiology. 1995 Aug;196(2):433-7 [7617857.001]
  • [Cites] Phys Med Biol. 1994 Oct;39(10):1629-38 [15551535.001]
  • (PMID = 17295924.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 85265; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / R01 CA085265; United States / NCI NIH HHS / CA / R01 CA63464; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CA / R37 CA 54281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 2.1.1.6 / Catechol O-Methyltransferase
  • [Other-IDs] NLM/ PMC1800856
  •  go-up   go-down


66. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E: Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res; 2006 Jan 15;12(2):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability.
  • PURPOSE: Most breast cancers have chromosomal instability that seems related to defective mitotic spindle checkpoints.
  • Because the molecular basis of this defect is unknown, we evaluated breast cancer cell lines and tissues for possible defects involving the major mitotic checkpoint genes responsible for maintaining chromosomal stability.
  • EXPERIMENTAL DESIGN: We analyzed sequences and expression levels (RNA and protein) of eight major spindle checkpoint genes (MAD1L1, MAD2L1, MAD2L2, BUB1, BUB1B, BUB3, CDC20, and TTK) in a panel of 12 breast cancer cell lines, most with established genetic instability and defective spindle damage checkpoint response. mRNA levels of these genes were also measured in primary tumor samples, and immunohistochemical staining was used to evaluate BUB1B protein levels in a panel of 270 additional cases of breast cancer.
  • RESULTS: No functionally significant sequence variations were found for any of the eight genes in the breast cancer cell lines with chromosomal instability.
  • More surprisingly, the mRNA and protein levels for these checkpoint genes are significantly higher in the genetically unstable breast cancer cell lines and in high-grade primary breast cancer tissues than in the stable (and checkpoint proficient) MCF-10A and normal mammary epithelial cells, or in normal breast tissues.
  • In fact, overexpression of the BUB1B protein is a marker that recognizes nearly 80% of breast cancers in paraffin-embedded tissues.
  • CONCLUSIONS: Defective mitotic spindle checkpoints in breast cancer are most likely not caused by low expression or mutations of these eight checkpoint genes.
  • High levels of these particular transcripts could represent a cellular compensation for defects in other molecular components of the mitotic spindle damage checkpoint, and increased expression of these genes might be markers of breast cancers with chromosomal instability.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. Protein Kinases / genetics. Spindle Apparatus / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Chromosome Fragility. Female. Genetic Variation. Humans. Mitosis / genetics. Protein-Serine-Threonine Kinases. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428479.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 88846-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BUB3 protein, human; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


67. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S: Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev; 2005 Sep;14(9):2137-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
  • BACKGROUND: It has been suggested that a low level of the 2-hydroxyestrogen metabolites (2-OHE) and a high level of 16alpha-hydroxyestrone (16alpha-OHE1) are associated with an enhanced risk of breast cancer.
  • We examined the association between the metabolite levels and breast cancer in a nested case-control study, which also addressed hormone replacement therapy (HRT) and estrogen receptor status of the tumors.
  • METHODS: 24,697 postmenopausal Danish women were enrolled in the "Diet, Cancer and Health" cohort.
  • During follow-up, 426 breast cancer cases were identified and controls were matched by age at diagnosis, baseline age, and HRT use.
  • The concentrations of 2-OHE and 16alpha-OHE1 in spot urine were measured by an enzyme immunoassay.
  • Incidence rate ratios (IRR) and 95% confidence intervals (95% CI) were estimated for total and estrogen receptor-specific breast cancer and were stratified according to HRT use.
  • RESULTS: A higher incidence of estrogen receptor-positive breast cancer with an enhanced 2-OHE level was observed among current HRT users, IRR per doubling = 1.30 (95% CI, 1.02-1.66), whereas no association was seen among nonusers of HRT, IRR per doubling = 1.00 (95% CI, 0.69-1.45).
  • The association between estrogen receptor-positive breast cancer and the 16alpha-OHE1 metabolite level was in the opposite direction but slightly weaker and statistically insignificant.
  • For estrogen receptor-negative breast cancer, no significant associations were seen.
  • CONCLUSIONS: The risk of breast cancer, in particular the estrogen receptor-positive type, was enhanced among postmenopausal women using estradiol-based HRT and among those who had a high 2-OHE concentration.
  • [MeSH-major] Breast Neoplasms / etiology. Estriol / analogs & derivatives. Hydroxyestrones / urine
  • [MeSH-minor] Biomarkers / analysis. Case-Control Studies. Female. Hormone Replacement Therapy. Humans. Middle Aged. Postmenopause. Receptors, Estrogen

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172222.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hydroxyestrones; 0 / Receptors, Estrogen; 1232-80-0 / 2-hydroxyestriol; 18186-49-7 / 16-hydroxyestrone; FB33469R8E / Estriol
  •  go-up   go-down


68. Jönsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR, Greshock JD, Luts L, Olsson H, Rahman N, Stratton M, Ringnér M, Borg A, Weber BL: Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res; 2005 Sep 1;65(17):7612-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
  • Mutations in BRCA1 and BRCA2 account for a significant proportion of hereditary breast cancers.
  • Tumor DNA was obtained from BRCA1 (n = 14) and BRCA2 (n = 12) mutation carriers, as well as sporadic cases (n = 26).
  • Overall, BRCA1 tumors had a higher frequency of copy number alterations than sporadic breast cancers (P = 0.00078).
  • Further validation may prove this tumor classifier to be useful for selecting familial breast cancer cases for further mutation screening, particularly, as these data can be obtained using archival tissue.
  • [MeSH-major] Breast Neoplasms / genetics. Genes, BRCA1. Genes, BRCA2. Mutation
  • [MeSH-minor] Gene Amplification. Gene Deletion. Gene Dosage. Gene Expression. Gene Expression Profiling. Genetic Predisposition to Disease. Humans. Nucleic Acid Hybridization


69. Taylor SF, Cook AE, Leatherbarrow B: Review of patients with basal cell nevus syndrome. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of patients with basal cell nevus syndrome.
  • PURPOSE: To review patients with basal cell nevus syndrome (BCNS), documenting presentation, referrals, treatment patterns, and associated morbidity.
  • Demographic data, age at presentation, age at diagnosis, spectrum of ophthalmic and periocular disease, treatment modalities used, and periocular deformities developed were reviewed.
  • Presenting clinical features included odontogenic keratocyst in 17 patients and basal cell carcinoma in 13 patients; less common presentations were with congenital malformations (n = 2), with ophthalmic associations (n = 3), and at genetic counseling (n = 4).
  • Seventeen of the 39 patients confirmed a parental diagnosis of BCNS.
  • Basal cell carcinoma developed in 18 of the 28 patients before the age of 30, confirming the reported early age of onset.
  • Periocular basal cell carcinoma was reported in 24 of 39 patients (61%), with recurrent disease reported in 17 of these 24 (71%), despite a variety of treatment modalities used.
  • CONCLUSIONS: Patients with BCNS frequently have ophthalmic manifestations, particularly periocular basal cell carcinoma.
  • Early diagnosis of BCNS may allow for skin protection and surveillance at an earlier age.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / pathology. Child. Child, Preschool. Cross-Sectional Studies. Eye Diseases / diagnosis. Eyelid Neoplasms / pathology. Female. Genetic Counseling. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Nevus.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855496.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Anderson BO: The Breast Health Global Initiative: why it matters to all of us. Oncology (Williston Park); 2010 Nov 30;24(13):1230-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Breast Health Global Initiative: why it matters to all of us.
  • The Breast Health Global Initiative (BHGI) applied an evidence-based consensus review process to the development of guidelines for breast cancer early detection, diagnosis, treatment and health care systems in low- and middle-income countries (LMCs).
  • Breast cancer outcomes correlate with the degree to which (1) cancers are detected at early stages, (2) newly detected cancers can be diagnosed correctly, and (3) appropriately selected multimodality treatment can be provided properly and in a timely fashion.
  • Cancer prevention through health behavior modification may influence breast cancer incidence in LMCs, although prevention strategies alone cannot eliminate the great majority of breast cancer cases.
  • Diagnosing breast cancer at earlier stages will reduce breast cancer mortality, assuming that appropriate multimodality treatment is provided.
  • Programs to promote breast self-awareness and clinical breast examination and resource-adapted mammographic screening are important steps in early detection.
  • Obstacles to breast cancer early detection, diagnosis, and treatment occur in industrialized countries as well as LMCs.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / prevention & control. Delivery of Health Care
  • [MeSH-minor] Early Detection of Cancer. Female. Global Health. Humans. International Cooperation. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Nov 30;24(13):1234-6 [21192565.001]
  • [CommentIn] Oncology (Williston Park). 2010 Nov 30;24(13):1236-7 [21192566.001]
  • [CommentIn] Oncology (Williston Park). 2010 Nov 30;24(13):1238 [21192567.001]
  • (PMID = 21192564.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Thomson BC, Ostle N, McNamara N, Bailey MJ, Whiteley AS, Griffiths RI: Vegetation affects the relative abundances of dominant soil bacterial taxa and soil respiration rates in an upland grassland soil. Microb Ecol; 2010 Feb;59(2):335-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vegetated soils had significantly increased carbon and nitrogen concentrations and exhibited higher rates of respiration.
  • This field-based study contributes to a growing body of evidence documenting the effect of soil nutrient status on the relative abundances of dominant soil bacterial taxa, with Proteobacterial taxa dominating over Acidobacteria in soils exhibiting higher rates of C turnover.

  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. CARBON .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 1981 Jan;41(1):97-9 [16345705.001]
  • [Cites] Appl Environ Microbiol. 2006 Jul;72(7):5069-72 [16820507.001]
  • [Cites] Nucleic Acids Res. 2004 Feb 25;32(4):1363-71 [14985472.001]
  • [Cites] Appl Environ Microbiol. 2005 Jun;71(6):2813-23 [15932972.001]
  • [Cites] Appl Environ Microbiol. 2001 Jan;67(1):172-8 [11133442.001]
  • [Cites] Science. 2004 Jun 11;304(5677):1629-33 [15192218.001]
  • [Cites] Appl Environ Microbiol. 2006 Mar;72(3):1852-7 [16517631.001]
  • [Cites] Appl Environ Microbiol. 2001 May;67(5):2284-91 [11319113.001]
  • [Cites] FEMS Microbiol Ecol. 2003 Feb 1;43(1):35-43 [19719694.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4742-51 [11571180.001]
  • [Cites] Appl Environ Microbiol. 1998 Feb;64(2):795-9 [9464425.001]
  • [Cites] Environ Microbiol. 2005 Jun;7(6):828-38 [15892702.001]
  • [Cites] Appl Environ Microbiol. 2007 Aug;73(16):5261-7 [17586664.001]
  • [Cites] Appl Environ Microbiol. 2006 Mar;72(3):1719-28 [16517615.001]
  • [Cites] Appl Environ Microbiol. 2000 Dec;66(12):5488-91 [11097934.001]
  • [Cites] Appl Environ Microbiol. 1997 Nov;63(11):4516-22 [9361437.001]
  • [Cites] Can J Microbiol. 2002 Jul;48(7):655-74 [12224564.001]
  • [Cites] Appl Environ Microbiol. 2004 Aug;70(8):4748-55 [15294811.001]
  • [Cites] Ecology. 2007 Jun;88(6):1354-64 [17601128.001]
  • [Cites] Antonie Van Leeuwenhoek. 2002 Aug;81(1-4):509-20 [12448746.001]
  • (PMID = 19705192.001).
  • [ISSN] 1432-184X
  • [Journal-full-title] Microbial ecology
  • [ISO-abbreviation] Microb. Ecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / RNA, Ribosomal, 16S; 0 / Soil; 142M471B3J / Carbon Dioxide; 7440-44-0 / Carbon
  •  go-up   go-down


72. Dong XY, Guo P, Boyd J, Sun X, Li Q, Zhou W, Dong JT: Implication of snoRNA U50 in human breast cancer. J Genet Genomics; 2009 Aug;36(8):447-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implication of snoRNA U50 in human breast cancer.
  • Deletion of chromosome 6q is frequent in breast cancer, and the deletion often involves a region in 6q14-q16.
  • Based on a recent study identifying snoRNA U50 as a candidate for the 6q14-16 tumor suppressor gene in prostate cancer, we investigated whether U50 is also involved in breast cancer.
  • PCR-based approaches showed that U50 underwent frequent genomic deletion and transcriptional downregulation in cell lines derived from breast cancer.
  • Mutation screening identified the same 2-bp deletion of U50 as in prostate cancer in both cell lines and primary tumors from breast cancer, and the deletion was both somatic and in germline.
  • Genotyping of a cohort of breast cancer cases and controls for the mutation demonstrated that, while homozygous genotype of the mutation was rare, its heterozygous genotype occurred more frequently in women with breast cancer.
  • Functionally, re-expression of U50 resulted in the inhibition of colony formation in breast cancer cell lines.
  • These results suggest that noncoding snoRNA U50 plays a role in the development and/or progression of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):76-84 [10564589.001]
  • [Cites] Mol Cancer Res. 2005 Sep;3(9):483-92 [16179495.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1125-9 [11078797.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):80-4 [11391625.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):173-93 [12085961.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):6041-9 [12473647.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5956-61 [12719539.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Nat Rev Genet. 2004 Apr;5(4):316-23 [15131654.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 6;81(23):1780-6 [2685334.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2724-8 [2328498.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Oct 15;49(2):203-17 [2170003.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1705-11 [1681492.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):551-9 [8094976.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):290-3 [7841042.001]
  • [Cites] Br J Cancer. 1996 Jan;73(2):144-7 [8546898.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):247-52 [8570202.001]
  • [Cites] Oncogene. 1996 Aug 15;13(4):677-85 [8761288.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8835-40 [9671765.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):806-11 [9743305.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1601-6 [9816339.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6897-909 [9819378.001]
  • [Cites] Hum Genet. 1998 Dec;103(6):727-9 [9921911.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):407-12 [15750593.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R121-32 [15809264.001]
  • [Cites] Science. 2006 Jan 13;311(5758):230-2 [16357227.001]
  • [Cites] BMC Cancer. 2006;6:92 [16608533.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6998-7006 [16849544.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):209-20 [17318225.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6220-8 [17384672.001]
  • [Cites] Hum Mol Genet. 2008 Apr 1;17(7):1031-42 [18202102.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4340-5 [18326623.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):195-208 [18836484.001]
  • [Cites] Am J Hum Genet. 2009 Feb;84(2):115-22 [19147119.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3880-3 [10919663.001]
  • (PMID = 19683667.001).
  • [ISSN] 1673-8527
  • [Journal-full-title] Journal of genetics and genomics = Yi chuan xue bao
  • [ISO-abbreviation] J Genet Genomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085560-09; United States / NCI NIH HHS / CA / CA085560-08; United States / NCI NIH HHS / CA / CA085560-09; United States / NCI NIH HHS / CA / R01CA085560; United States / NCI NIH HHS / CA / R01 CA085560; United States / NCI NIH HHS / CA / R01 CA085560-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Nucleolar
  • [Other-IDs] NLM/ NIHMS192689; NLM/ PMC2854654
  •  go-up   go-down


73. Uhrhammer N, Delort L, Bignon YJ: Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):684-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population.
  • Mutations in DNA repair genes are known for their association with hereditary breast cancer.
  • BRCA1 and BRCA2 are the major genes for high-penetrance familial breast and ovarian cancer, whereas mutations in ATM or Chek2 confer more modest cancer risk.
  • Additional genes involved in DNA double-strand break repair have more recently been associated with breast cancer risk: heterozygosity for deleterious mutations in components of the Rad50-Mre11-Nbs1 complex seems to predispose to breast cancer.
  • In particular, the c.687delT mutation in Rad50 conferred an odds ratio of 4.3 for the risk of breast cancer in a study of Finnish breast cancer families.
  • To explore the contribution of this mutation to breast cancer in French families for which no BRCA mutation could be found, we analyzed the relevant exon in 618 familial breast cancer cases and 513 controls with no personal or familial history of breast cancer.
  • Rad50 was analyzed in its entirety for 231 familial cases, with no clearly deleterious mutations detected.
  • These data together suggest that although founder mutations may make Rad50 a significant breast cancer risk factor in certain populations, it is not a factor in others.
  • [MeSH-major] Breast Neoplasms / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190165.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Rad50 protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


74. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Wijers-Koster PM, Blom JC, Pooley KA, Klijn JG, Tollenaar RA, Devilee P, van Asperen CJ: Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res; 2007;9(6):R78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.
  • INTRODUCTION: Seven SNPs in five genomic loci were recently found to confer a mildly increased risk of breast cancer.
  • METHODS: We have investigated the correlations between disease characteristics and the patient genotypes of these SNPs in an unselected prospective cohort of 1,267 consecutive patients with primary breast cancer.
  • RESULTS: Heterozygote carriers and minor allele homozygote carriers for SNP rs889312 in the MAP3K1 gene were less likely to be lymph node positive at breast cancer diagnosis (P = 0.044) relative to major allele homozygote carriers.
  • We also noted a correlation between the number of minor alleles of rs2981582 in FGFR2 and the average number of first-degree and second-degree relatives with breast cancer and/or ovarian cancer (P = 0.05).
  • All other disease characteristics, including tumour size and grade, and oestrogen or progesterone receptor status, were not significantly associated with any of these variants.
  • CONCLUSION: Some recently discovered genomic variants associated with a mildly increased risk of breast cancer are also associated with breast cancer characteristics or family history of breast cancer and ovarian cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Chromosomes, Human, Pair 8. MAP Kinase Kinase Kinase 1 / genetics. Microfilament Proteins / genetics. Polymorphism, Single Nucleotide. Receptor, Fibroblast Growth Factor, Type 2 / genetics. Receptors, Progesterone / genetics
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Genetic Predisposition to Disease. Humans. Incidence. Lymphatic Metastasis. Middle Aged. Netherlands / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Dec;26(4):411-4 [11101836.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1389-99 [11705483.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2310-8 [11981002.001]
  • [Cites] J Med Genet. 2003 Jul;40(7):e83 [12843332.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1175-82 [15122511.001]
  • [Cites] J Med Genet. 2004 Oct;41(10):731-5 [15466005.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):921-4 [9637142.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45 [9701363.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):943-9 [10359546.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):850-60 [15516958.001]
  • [Cites] Hum Mol Genet. 2005 Feb 15;14(4):555-63 [15649950.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):377-82 [15925815.001]
  • [Cites] Growth Factors. 2006 Mar;24(1):45-53 [16393693.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1693-700 [16551851.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):646-55 [16575876.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):611-7 [16603649.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jul;59(1):27-39 [16530420.001]
  • [Cites] Int J Gynecol Cancer. 2006;16 Suppl 2:552-5 [17010071.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1239-41 [17033622.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):64-9 [17132695.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):165-7 [17200668.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):103-5 [17292821.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):870-4 [17529973.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):865-9 [17529974.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5878-87 [11593393.001]
  • (PMID = 17997823.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / LSP1 protein, human; 0 / Microfilament Proteins; 0 / Receptors, Progesterone; 0 / TNRC9 protein, human; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; EC 2.7.11.25 / MAP Kinase Kinase Kinase 1; EC 2.7.11.25 / MAP3K1 protein, human
  • [Other-IDs] NLM/ PMC2246176
  •  go-up   go-down


75. Douglas HE, Agarwal R, Lam DG: 'Teenage BCC: to tan or not to tan?'. J Plast Reconstr Aesthet Surg; 2008 Oct;61(10):1245-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Teenage BCC: to tan or not to tan?'.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541465.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


76. Heo ST, Kim SJ, Jeong YG, Bae IG, Jin JS, Lee JC: Hospital outbreak of Burkholderia stabilis bacteraemia related to contaminated chlorhexidine in haematological malignancy patients with indwelling catheters. J Hosp Infect; 2008 Nov;70(3):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Burkholderia cepacia complex (BCC) is an opportunistic pathogen that occasionally causes hospital outbreaks.
  • This paper describes an outbreak of BCC bacteraemia in haematological malignancy patients related to a contaminated chlorhexidine gluconate solution.
  • Eight BCC isolates were obtained from patients hospitalised in the same ward of a cancer centre in a Korean hospital.
  • A further three BCC isolates were obtained from 0.5% chlorhexidine gluconate used in the same ward.
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Burkholderia / isolation & purification. Catheters, Indwelling / microbiology. Child. Disease Outbreaks. Electrophoresis, Gel, Pulsed-Field. Female. Hematologic Neoplasms / complications. Hospitals, Teaching. Humans. Infection Control / methods. Korea / epidemiology. Male. Middle Aged. Young Adult

  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799235.001).
  • [ISSN] 0195-6701
  • [Journal-full-title] The Journal of hospital infection
  • [ISO-abbreviation] J. Hosp. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents, Local; MOR84MUD8E / chlorhexidine gluconate; R4KO0DY52L / Chlorhexidine
  •  go-up   go-down


77. Limtong S, Yongmanitchai W: Candida chanthaburiensis sp. nov., Candida kungkrabaensis sp. nov. and Candida suratensis sp. nov., three novel yeast species from decaying plant materials submerged in water of mangrove forests. Antonie Van Leeuwenhoek; 2010 Oct;98(3):379-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were named as Candida chanthaburiensis sp. nov. (type strain EM33(T) = BCC 23057(T) = NBRC 102176(T) = CBS 10926(T)), Candida kungkrabaensis sp. nov. (type strain EM40(T) = BCC 23060(T) = NBRC 102179(T) = CBS 10927(T)), and Candida suratensis sp. nov. (type strain SM56(T) = BCC 25961(T) = NBRC 103858(T) = CBS 10928(T)).

  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • SILVA. SILVA LSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467812.001).
  • [ISSN] 1572-9699
  • [Journal-full-title] Antonie van Leeuwenhoek
  • [ISO-abbreviation] Antonie Van Leeuwenhoek
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / DNA, Ribosomal; 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


78. Loncaster J, Swindell R, Slevin F, Sheridan L, Allan D, Allan E: Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas. Clin Oncol (R Coll Radiol); 2009 Aug;21(6):502-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas.
  • AIMS: The management of the multiple basal cell carcinomas (BCCs) that develop throughout life of patients with Gorlin syndrome can be challenging.
  • Photodynamic therapy (PDT) is a simple, repeatable out-patient procedure, which is associated with minimal skin deterioration.
  • It is now routinely used to treat superficial sporadic BCCs, using a topically-applied photosensitiser and external light, but its role in the management of Gorlin syndrome-related BCCs has yet to be established.
  • The use of a systemic photosensitiser +/- interstitial light delivery extended the remit of PDT, allowing thicker lesions (>2 mm) to be treated, resulting in local control rates of 59.3% in this group.
  • PDT can be considered as a treatment option for patients with multiple BCCs as a result of Gorlin syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398312.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


79. Castori M, Castiglia D, Passarelli F, Paradisi M: Bazex-Dupré-Christol syndrome: an ectodermal dysplasia with skin appendage neoplasms. Eur J Med Genet; 2009 Jul-Aug;52(4):250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bazex-Dupré-Christol syndrome: an ectodermal dysplasia with skin appendage neoplasms.
  • Bazex-Dupré-Christol syndrome is a rare X-linked genodermatosis characterized by early-onset nonmelanoma skin cancers, atrophoderma follicularis, hypotrichosis, hypohidrosis, and multiple milia.
  • We report a 5-year-old child presenting sparse hair, reduced sweating, ice-pick skin depressions of the dorsum of hands, facial and limb milia, perianal skin hyperpigmentation, and hyperpigmented papules of the axillae and neck.
  • Histologic examination of a skin papule obtained from the index case revealed features consistent with trichoepithelioma.
  • Our findings indicate that trichoepitheliomas are an early sign of Bazex-Dupré-Christol syndrome and may guide the diagnosis even before the development of basal cell carcinomas.
  • The high frequency of hypotrichosis, hypohidrosis and dry skin in Bazex-Dupré-Christol syndrome indicates that it may be better classified as an ectodermal dysplasia.
  • Comparison with other conditions combining features of ectodermal dysplasia and proneness to skin tumors suggests the involvement of a common pathogenic pathway implicated in both skin development and cancer.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / pathology. Ectodermal Dysplasia / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Hair / pathology. Humans. Hyperpigmentation / diagnosis. Hyperpigmentation / pathology. Hypohidrosis / diagnosis. Hypohidrosis / physiopathology. Hypotrichosis / diagnosis. Hypotrichosis / pathology. Male


80. Lovato L, Salerni G, Puig S, Carrera C, Palou J, Malvehy J: Adult xanthogranuloma mimicking basal cell carcinoma: dermoscopy, reflectance confocal microscopy and pathological correlation. Dermatology; 2010;220(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult xanthogranuloma mimicking basal cell carcinoma: dermoscopy, reflectance confocal microscopy and pathological correlation.
  • Juvenile xanthogranuloma in adulthood is an infrequent non-Langerhans cell histiocytosis, which may simulate malignant tumors such as basal cell carcinoma (BCC) or amelanotic melanoma.
  • Dermoscopy has been described as a useful tool in the preoperative diagnosis of xanthogranuloma.
  • We report a xanthogranuloma on the suprapubic area of a 48-year-old female, which clinically and dermoscopically mimicked a BCC with a yellowish hue and arborizing vessels.
  • To our knowledge this is the first description of the clinical, dermoscopic and confocal microscopy correlations of a xanthogranuloma.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Xanthogranuloma, Juvenile / diagnosis
  • [MeSH-minor] Cell Nucleus / ultrastructure. Dermoscopy. Diagnosis, Differential. Female. Humans. Microscopy, Confocal. Middle Aged

  • Genetic Alliance. consumer health - Xanthogranuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] J Cutan Pathol. 2017 Sep;44(9):809-810 [28671710.001]
  • (PMID = 19996569.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


81. Oda E, Nakamura Y, Yamamoto M, Kojiro M: Immunohistochemical distribution of tubulin beta II in human normal and neoplastic tissues. Kurume Med J; 2005;52(4):117-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We obtained normal tissues from 33 cases (8 fetuses, 17 neonates, 3 children and 5 adults) and 121 samples of neoplastic tissue from surgical specimens or at autopsy.
  • Tubulin beta II was detected in various normal tissues, particularly in fetal and neonatal tissues, such as the nervous system, pulmonary alveoli, bronchioles and bronchi, colon, pancreatic ducts and acini, renal convoluted tubuli, skin epidermis, body cavity mesothelial cells, smooth muscle and thymus.
  • In neoplastic tissues, tubulin beta II immunoreactivity was detected in various nervous system neoplasms and other neoplasms such as pancreatic solid cystic carcinoma, pleomorphic adenoma, Warthin's tumor, nephroblastoma, basal cell carcinoma and malignant mesothelioma.
  • We conclude that our monoclonal antibody, KNY379, may be useful as a marker of nervous system neoplasm, pancreatic solid cystic carcinoma, pleomorphic adenoma, Warthin's tumor, nephroblastoma, basal cell carcinoma and malignant mesothelioma.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639982.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / Tubulin
  •  go-up   go-down


82. Schmitt J, Diepgen T, Bauer A: Occupational exposure to non-artificial UV-light and non-melanocytic skin cancer - a systematic review concerning a new occupational disease. J Dtsch Dermatol Ges; 2010 Apr;8(4):250-63, 250-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to non-artificial UV-light and non-melanocytic skin cancer - a systematic review concerning a new occupational disease.
  • BACKGROUND: Although UV exposure is the most important risk factor for cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), a systematic review analyzing the risk of occupational UV exposure is missing.
  • METHODS: Based on a systematic literature search in PubMed (until 05/2009) supplemented by hand search, the association between occupational UV exposure and SCC and BCC was analyzed.
  • The association between occupational UV exposure and cancer risk is presented as odds ratios (OR).
  • RESULTS: We identified 25 relevant epidemiologic studies (5 cohort studies, 17 case-control studies, 3 cross-sectional studies).
  • A significant positive association between occupational UV exposure and BCC was reported in 5 studies; 11 studies did not find a significant association.
  • CONCLUSIONS: The association between occupational UV exposure and SCC is well and consistently documented epidemiologically (approximately 2-fold increased risk), so that the criteria for a new occupational disease are fulfilled.
  • The association with BCC is unclear due to significant methodological limitations in the published studies.
  • [MeSH-major] Neoplasms, Radiation-Induced / epidemiology. Occupational Diseases / epidemiology. Occupational Exposure / statistics & numerical data. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832928.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


83. Moriya T, Kanomata N, Kozuka Y, Hirakawa H, Kimijima I, Kimura M, Watanabe M, Sasano H, Ishida T, Ohuchi N, Kurebayashi J, Sonoo H: Molecular morphological approach to the pathological study of development and advancement of human breast cancer. Med Mol Morphol; 2010 Jun;43(2):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular morphological approach to the pathological study of development and advancement of human breast cancer.
  • Particularly, triplenegative (TN) breast cancer, which is negative for all hormone receptors [estrogen receptor (ER) and/or progesterone receptor (PgR) and human epidermal growth factor 2 (HER2)], has been attracting attention because effects of endocrine and targeting therapies cannot be anticipated and thus selecting a treatment method is difficult.
  • TN cancer accounts for about 10%-15% of all invasive breast cancer cases in Japanese, which is significantly lower than the incidence reported in the United States.
  • Cytokeratin (CK) 5/6 or epidermal growth factor receptor (EGFR) is positive in 80%, being classified as basal-like carcinoma, but it should be understood that TN breast cancer and basal-like carcinoma are not necessarily the same.
  • Criteria for positivity judgment of ER, PgR, and HER2 were established to select treatment in cases positive for each marker, and greater importance is attached to strict accuracy control.
  • In any case, the prognosis of TN breast cancer is poor.
  • Pathologically, TN breast cancer shows certain morphological characteristics, such as high grade and a pushing margin, and abnormalities of BRCA1 and p53 are frequently noted.
  • At present, as no effective therapeutic strategy has been established for TN breast cancer, further clarification of the molecular biological characteristics of such cancers is needed.
  • In addition, the incidence of TN-type ductal carcinoma in situ (DCIS) is low, suggesting that TN does not remain preinvasive DCIS for a prolonged period and that it transforms to invasive cancer in an early stage.
  • Because mammary gland basal cells have characters of progenitor or stem cells that differentiate into both luminal epithelium and myoepithelial cells, these cells may be utilized for the differential diagnosis of the benignity or malignancy of intraductal lesions in routine pathological practice.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Disease Progression


84. Shuster S: Mohs' micrographic surgery for basal-cell carcinoma of the face. Lancet; 2005 Apr 2-8;365(9466):1227-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mohs' micrographic surgery for basal-cell carcinoma of the face.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Mohs Surgery
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • (PMID = 15811450.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


85. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G: Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med; 2007 Jun 11;204(6):1441-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imiquimod (IMQ), a synthetic agonist to Toll-like receptor (TLR) 7, is being successfully used for the treatment of certain skin neoplasms, but the exact mechanisms by which this compound induces tumor regression are not yet understood.
  • While treating basal cell carcinoma (BCC) patients with topical IMQ, we detected, by immunohistochemistry, sizable numbers of both myeloid dendritic cells (mDCs) and plasmacytoid DCs (pDCs) within the inflammatory infiltrate.
  • The biological relevance of this observation can be deduced from our further findings that peripheral blood-derived CD11c(+) mDCs acquired antiperforin and anti-granzyme B reactivity upon TLR7/8 stimulation and could use these molecules to effectively lyse major histocompatibility complex (MHC) class I(lo) cancer cell lines.
  • While suggesting that mDCs and pDCs are directly involved in the IMQ-induced destruction of BCC lesions, our data also add a new facet to the functional spectrum of DCs, ascribing to them a major role not only in the initiation but also in the effector phase of the immune response.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / immunology. Dendritic Cells / immunology. Toll-Like Receptor 7 / metabolism. Toll-Like Receptor 8 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal. Cell Line, Tumor. Cytotoxicity Tests, Immunologic. Female. Flow Cytometry. Granzymes / immunology. Humans. Immunohistochemistry. Leukocytes / chemistry. Male. Perforin / immunology. TNF-Related Apoptosis-Inducing Ligand / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] Nature. 1997 Jul 24;388(6640):394-7 [9237759.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):317-22 [12949814.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8628-33 [14634624.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1181-6 [14725659.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):262-9 [14757443.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1529-31 [14976261.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1526-9 [14976262.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):499-511 [15229469.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3051-61 [15322165.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):485-8 [15327559.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):505-12 [15347337.001]
  • [Cites] Cutis. 2004 Aug;74(2):134-8, 141-2 [15379366.001]
  • [Cites] Br J Dermatol. 2004 Oct;151(4):903-6 [15491436.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3528-33 [1377595.001]
  • [Cites] J Interferon Res. 1994 Apr;14(2):81-5 [8077768.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):803-8 [11238028.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):863-9 [11561001.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3565-9 [11564767.001]
  • [Cites] Eur J Immunol. 2001 Nov;31(11):3138-46 [11745330.001]
  • [Cites] Eur J Immunol. 2001 Nov;31(11):3388-93 [11745357.001]
  • [Cites] FASEB J. 2002 Feb;16(2):213-5 [11772948.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1823-30 [11823515.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1831-9 [11823516.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1251-62 [11850845.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3295-303 [12384430.001]
  • [Cites] Immunol Lett. 2003 Jan 22;85(2):85-95 [12527213.001]
  • [Cites] Immunity. 2003 Jul;19(1):59-70 [12871639.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] J Immunol. 1996 May 15;156(10):3678-86 [8621902.001]
  • [Cites] J Immunol Methods. 1996 Jun 21;193(2):199-206 [8699033.001]
  • [Cites] Immunity. 1997 Dec;7(6):831-6 [9430228.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1451-60 [10224285.001]
  • [Cites] J Exp Med. 1999 Oct 18;190(8):1155-64 [10523613.001]
  • [Cites] Clin Exp Dermatol. 2004 Nov;29(6):639-43 [15550144.001]
  • [Cites] J Cell Physiol. 2005 Mar;202(3):900-11 [15389633.001]
  • [Cites] Int J Dermatol. 2005 Jan;44(1):14-9 [15663652.001]
  • [Cites] J Pathol. 2005 Mar;205(4):426-34 [15714455.001]
  • [Cites] Aust Fam Physician. 2005 Jan-Feb;34(1-2):49-52 [15727358.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4127-34 [15778372.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):467-73 [15837864.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):318-23 [15841634.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1143-53 [16077073.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2408-17 [16081812.001]
  • [Cites] Science. 2005 Aug 26;309(5739):1380-4 [16123302.001]
  • [Cites] Eur J Dermatol. 2005 Sep-Oct;15(5):374-81 [16172048.001]
  • [Cites] Int Arch Allergy Immunol. 2005 Dec;138(4):278-90 [16220004.001]
  • [Cites] J Drugs Dermatol. 2005 Nov-Dec;4(6):708-17 [16302556.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):248-55 [16365416.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19057-62 [16380428.001]
  • [Cites] Acta Clin Belg. 2005 Sep-Oct;60(5):227-34 [16398319.001]
  • [Cites] Nat Med. 2006 Feb;12(2):214-9 [16444265.001]
  • [Cites] Nat Med. 2006 Feb;12(2):207-13 [16444266.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):311-7 [16462739.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1338-47 [16575388.001]
  • [Cites] Int J STD AIDS. 2006 Jul;17(7):448-52 [16820073.001]
  • (PMID = 17535975.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / TLR7 protein, human; 0 / TLR8 protein, human; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptor 8; 126465-35-8 / Perforin; 99011-02-6 / imiquimod; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2118597
  •  go-up   go-down


86. Eskira S, Gilad J, Schlaeffer P, Hyam E, Peled N, Karakis I, Riesenberg K, Schlaeffer F, Borer A: Reduction of blood culture contamination rate by an educational intervention. Clin Microbiol Infect; 2006 Aug;12(8):818-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of an educational intervention to prevent blood culture contamination (BCC) in internal medicine was studied in two medical wards in a busy tertiary-care hospital in which blood cultures were obtained by physicians rather than dedicated phlebotomists.
  • Baseline BCC rates were 5.7% and 7.1% in intervention and control wards, respectively (p 0.6), compared with 1.95% and 6.7%, respectively, post-intervention (p < 0.001).
  • Following multivariate analysis, only an absence of intervention was an independent variable associated with BCC.
  • Thus simple educational intervention reduced BCC in internal medicine and was considered to be cost-effective.
  • [MeSH-major] Bacteremia / diagnosis. Blood / microbiology. Blood Specimen Collection / methods. Disinfection
  • [MeSH-minor] Cycloheximide / administration & dosage. Equipment Contamination / prevention & control. Ethanol / administration & dosage. Humans. Skin / microbiology

  • MedlinePlus Health Information. consumer health - Blood.
  • MedlinePlus Health Information. consumer health - Germs and Hygiene.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Microbiol Infect. 2007 Jan;13(1):110-1 [17184302.001]
  • [CommentIn] Clin Microbiol Infect. 2007 Jan;13(1):109; author reply 109-10 [17184301.001]
  • (PMID = 16842584.001).
  • [ISSN] 1198-743X
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 3K9958V90M / Ethanol; 98600C0908 / Cycloheximide
  •  go-up   go-down


87. Ramos-Ceballos FI, Pashaei S, Kincannon JM, Morgan MB, Smoller BR: Bcl-2, CD34 and CD10 expression in basaloid follicular hamartoma, vellus hair hamartoma and neurofollicular hamartoma demonstrate full follicular differentiation. J Cutan Pathol; 2008 May;35(5):477-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Generalized basaloid follicular hamartoma syndrome (GBFHS) is a rare, recently-described, autosomal-dominantly inherited disorder that presents with disseminated milia, palmoplantar pitting, hypotrichosis and basaloid follicular hamartomas (BFH).
  • BFH is a benign adnexal tumor that resembles basal cell carcinoma (BCC).
  • In this study, we report two cases of GBFHS and stain BFH, a vellus hair hamartoma (VHH) and a neurofollicular hamartoma (NH) with CD34, bcl-2 and CD10 to characterize and compare the staining patterns of these follicular tumors.
  • Bcl-2 stained the outermost cell layers of the basaloid nests in all specimens.
  • Bcl-2 stains the outermost cell layer of these tumors.

  • Genetic Alliance. consumer health - Basaloid Follicular Hamartoma.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2009 May;36(5):603; author reply 604 [19476535.001]
  • (PMID = 18399809.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


88. Fallschissel K, Klug K, Kämpfer P, Jäckel U: Detection of airborne bacteria in a German turkey house by cultivation-based and molecular methods. Ann Occup Hyg; 2010 Nov;54(8):934-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Today's large-scale poultry production with densely stocked and enclosed production buildings is often accompanied by very high concentrations of airborne microorganisms leading to a clear health hazard for employees working in such environments.
  • In this study, turkey houses bioaerosols were investigated by cultivation-based and molecular methods in parallel to determine the concentrations and the composition of bacterial community.

  • MedlinePlus Health Information. consumer health - Indoor Air Pollution.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20720091.001).
  • [ISSN] 1475-3162
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aerosols; 0 / Air Pollutants, Occupational; 0 / Dust; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


89. Moharita AL, Taborga M, Corcoran KE, Bryan M, Patel PS, Rameshwar P: SDF-1alpha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. Blood; 2006 Nov 15;108(10):3245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SDF-1alpha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis.
  • Breast cancer cells (BCCs) show preference for the bone marrow (BM).
  • An animal model showed 2 populations of BCCs in the BM with regard to their cycling states.
  • Here, we show a critical role for BCC-derived SDF-1alpha in hematopoietic regulation.
  • The studies used a coculture of BM stroma and BCCs (cell lines and stage II BCCs).
  • Northern blots and enzyme-linked immunosorbent assay (ELISA) showed gradual decreases in SDF-1alpha production in BCCs as they contact BM stroma, indicating partial microenvironmental effects caused by stroma on the BCCs.
  • SDF-1 knock-down BCCs and increased exogenous SDF-1alpha prevented contact inhibition between BCCs and BM stroma.
  • Long-term culture-initiating assays with CD34(+)/CD38(-)/Lin(-) showed normal hematopoiesis provided that SDF-1alpha levels were reduced in BCCs.
  • Gap junctions (connexin-43 [CX-43]) were formed between BCCs and BM stroma, with concomitant interaction between CD34(+)/CD38(-)/Lin(-) and BM stroma but not with the neighboring BCCs.
  • In summary, SDF-1alpha levels are reduced in BCCs that contact BM stroma.
  • The low levels of SDF-1alpha in BCCs regulate interactions between BM stroma and hematopoietic progenitors, consequently facilitating normal hematopoiesis.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Communication. Chemokines, CXC / physiology. Hematopoiesis. Stromal Cells / pathology
  • [MeSH-minor] Aged. Animals. Bone Marrow Cells / pathology. Chemokine CXCL12. Coculture Techniques. Contact Inhibition. Female. Gap Junctions. Humans. Mice. Middle Aged. Neoplasm Proteins. RNA, Small Interfering / pharmacology

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857992.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


90. Schwartz JL, Kopecky KJ, Mathes RW, Leisenring WM, Friedman DL, Deeg HJ: Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res; 2009 Feb;171(2):155-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation.
  • Previous studies identified radiation therapy as a key modifier of basal cell carcinoma (BCC) risk in survivors of hematopoietic cell transplantation (HCT).
  • In the present analysis, risk of BCC was analyzed in relation to age at transplant, attained age, race, total-body irradiation (TBI), and radiation fractionation in 6,306 patients who received HCT at ages 0-65 years after conditioning regimens with (n = 3870) or without (n = 2436) TBI, and who were followed from 100 days to 36.2 years after HCT.
  • While age-specific BCC rates in the unirradiated patient population were higher than those reported for two non-patient populations, the general characteristics were similar; rates increased with attained age, were eightfold lower for non-white patients, and were higher in more recent birth cohorts.
  • The additional BCC risk associated with radiation exposure was largest for the youngest ages at exposure to radiation, with relative risks exceeding 20 for those transplanted at ages less than 10 years, and decreased with increasing age at exposure until age 40 years, above which no excess risk was identified.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 1987 Jun;110(3):458-67 [3588850.001]
  • [Cites] Int J Radiat Biol. 1990 Apr;57(4):809-27 [1969909.001]
  • [Cites] J Am Acad Dermatol. 1990 May;22(5 Pt 1):859-60 [2347978.001]
  • [Cites] Radiat Res. 1991 Mar;125(3):318-25 [2000456.001]
  • [Cites] Med Pediatr Oncol. 1991;19(6):508-10 [1961139.001]
  • [Cites] Int J Hematol. 1993 Dec;59(1):67-71 [8161737.001]
  • [Cites] Health Phys. 1995 Jul;69(1):93-101 [7790217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):419-24 [8781736.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53 [8961975.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1833-44 [9490664.001]
  • [Cites] Blood. 1998 May 15;91(10):3637-45 [9572999.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):393-401 [9794171.001]
  • [Cites] Ann ICRP. 1998;28(1-2):1-157 [10406427.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3733-41 [15923570.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1119-26 [16461782.001]
  • [Cites] Arch Dermatol. 2000 Aug;136(8):1007-11 [10926736.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1224-9 [11122025.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Radiat Res. 2002 Apr;157(4):410-8 [11893243.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):634-8 [15373766.001]
  • [Cites] Radiat Res. 1985 Jun;102(3):378-91 [4070552.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):411-4 [3791154.001]
  • (PMID = 19267540.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102542-05; United States / NCI NIH HHS / CA / R01 CA102542-04; United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA102542-03; United States / NCI NIH HHS / CA / R01 CA102542-05; United States / NCI NIH HHS / CA / CA102542; United States / NCI NIH HHS / CA / R01 CA102542; United States / NCI NIH HHS / CA / CA102542-02; United States / NCI NIH HHS / CA / R01 CA102542-01A1; United States / NCI NIH HHS / CA / CA102542-04; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / CA102542-01A1; United States / NCI NIH HHS / CA / R01 CA102542-03; United States / NHLBI NIH HHS / HL / P01 HL036444; United States / NCI NIH HHS / CA / R01 CA102542-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS93674; NLM/ PMC2662700
  •  go-up   go-down


91. Imiquimod: new indication. Basal cell carcinoma: inferior to other treatments. Prescrire Int; 2006 Aug;15(84):130-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod: new indication. Basal cell carcinoma: inferior to other treatments.
  • (1) Basal cell carcinoma is a common malignancy that is rarely life-threatening.
  • The main alternative is radiotherapy. (2) The Indications section of the Summary of Product Characteristics (SPC) for imiquimod cream in Europe now includes "topical treatment of small superficial basal cell carcinomas in adults". (3) Imiquimod cream was primarily evaluated in 2 double-blind randomised controlled trials versus excipient, in a total of 724 patients.
  • In these trials, small basal cell tumours (maximum 2 cm in diameter) disappeared in three-quarters of patients after imiquimod application 5 or 7 days a week for six weeks. (4) A non comparative trial involving 143 patients showed a relapse rate of 21% at 2 years.
  • Indirect comparisons show that this is a much higher relapse rate than after other well-assessed treatments for basal cell cancer. (5) During clinical trials, nearly one-third of patients who used imiquimod 5 times a week complained of pruritus, a burning sensation, or local pain.
  • [MeSH-major] Aminoquinolines. Carcinoma, Basal Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989024.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments
  •  go-up   go-down


92. Cuffy M, Abir F, Longo WE: Management of less common tumors of the colon, rectum, and anus. Clin Colorectal Cancer; 2006 Jan;5(5):327-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of colorectal and anal malignancies are adenocarcinomas and squamous cell cancers, respectively.
  • These tumors often present challenges to clinicians with respect to diagnosis, staging, management, and pathology because of their unfamiliarity.
  • A Medline search using "colon," "rectum,""anus," "lymphoma," "melanoma," "diffuse cavernous hemangioma," "squamous cell carcinoma," "carcinoid," "sarcoma," "leiomyosarcoma," "Kaposi's sarcoma," "Paget's disease," "Bowen's disease," and "basal cell carcinoma" as key words was performed as well as a cross-referencing of the bibliography cited in each work.
  • For some histotypes, such as squamous cell carcinoma and carcinoids of the rectum, treatment depends on location and size of the tumor.
  • For uncommon anal lesions, such as Bowen's disease, Paget's disease, and basal cell carcinoma, wide local excision (WLE) with negative margins is the standard of care.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Colonic Neoplasms / therapy. Hemangioma, Cavernous / therapy. Lymphoma / therapy. Neuroendocrine Tumors / therapy. Rectal Neoplasms / therapy. Sarcoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512991.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 164
  •  go-up   go-down


93. Błachowski A, Ruebenbauer K, Rakowska A, Kac S: Fractal-like behaviour of the BCC/FCC phase separation in the iron-gold alloys. J Microsc; 2010 Mar;237(3):395-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractal-like behaviour of the BCC/FCC phase separation in the iron-gold alloys.
  • The alloys were composed of two phases, i.e. a BCC phase rich in iron and a FCC phase rich in gold.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20500404.001).
  • [ISSN] 1365-2818
  • [Journal-full-title] Journal of microscopy
  • [ISO-abbreviation] J Microsc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Haneke E: [Precancerous and early invasive carcinomas: non-surgical treatment of head and facial skin]. HNO; 2009 Apr;57(4):315-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Precancerous and early invasive carcinomas: non-surgical treatment of head and facial skin].
  • Chronic exposure to sunlight with its high proportion of high energy ultraviolet light is the main cause of the common cutaneous precancerous lesions and carcinomas of the head and neck.
  • This causes a field cancerization effect frequently with multiple actinic keratoses (AKs), basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs).
  • Intralesional and perilesional injections of cytotoxic agents and interferons as well as the new targeted anti-cancer drugs are further alternatives.
  • [MeSH-major] Facial Neoplasms / diagnosis. Facial Neoplasms / therapy. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Precancerous Conditions / diagnosis. Precancerous Conditions / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Dermatology / trends. Humans. Neoplasm Invasiveness. Otolaryngology / trends

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877-8 [16898919.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):943-4 [12873902.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):944-5 [12873903.001]
  • [Cites] Dermatol Surg. 2006 Mar;32(3):380-6 [16640683.001]
  • [Cites] Australas J Dermatol. 2006 Aug;47(3):186-8 [16867000.001]
  • [Cites] Vaccine. 2004 Apr 16;22(13-14):1799-809 [15068864.001]
  • [Cites] Int J Pharm. 2008 Apr 2;353(1-2):233-42 [18191509.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):562-4 [12459528.001]
  • [Cites] Jpn J Ophthalmol. 2006 Jul-Aug;50(4):305-11 [16897213.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):371-4 [15841646.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1767-8 [10610445.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):160-6 [15725922.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Clin Exp Dermatol. 2006 Sep;31(5):721-2 [16780500.001]
  • [Cites] J Drugs Dermatol. 2005 Nov-Dec;4(6):708-17 [16302556.001]
  • [Cites] Drugs. 2006;66(13):1657-64 [16978032.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):945-7 [12873904.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2359s-2365s [16609059.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):674-83 [16855373.001]
  • [Cites] Dermatol Online J. 2006 Mar 30;12(3):25 [16638439.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):319-24 [11255332.001]
  • [Cites] Dermatol Surg. 2008 Jul;34(7):859-72 [18363724.001]
  • [Cites] J Am Acad Dermatol. 1998 Mar;38(3):438-42 [9520026.001]
  • [Cites] Semin Cutan Med Surg. 2008 Mar;27(1):52-62 [18486025.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):849-61 [17052492.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Clin Exp Dermatol. 2005 Nov;30(6):717-8 [16197401.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):742-50 [16881970.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] J Am Acad Dermatol. 2007 Mar;56(3):422-5 [17184874.001]
  • [Cites] Eur J Dermatol. 2000 Oct-Nov;10(7):568-75; discussion 576 [11056436.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] J Invest Dermatol. 2006 Feb;126(2):265-71 [16374471.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:13-5 [14616805.001]
  • [Cites] Eur J Dermatol. 2004 Mar-Apr;14 (2):96-102 [15196999.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2635-45 [18442098.001]
  • [Cites] Clin Exp Dermatol. 2006 Sep;31(5):717-8 [16901322.001]
  • [Cites] Eur J Dermatol. 2006 Jul-Aug;16(4):335-9 [16935787.001]
  • [Cites] J Am Acad Dermatol. 2008 Apr;58(4):585-91 [18068265.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):81-7 [17126745.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] Apoptosis. 2004 May;9(3):291-8 [15258460.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):1092-4 [17097406.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] Int J Dermatol. 2006 Jul;45(7):854-6 [16863526.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):16-8 [15720089.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1251-5 [16557235.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153 [14641346.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Feb;4(2):108-13 [16503937.001]
  • [Cites] J Photochem Photobiol B. 1992 Jul 30;14 (4):275-92 [1403373.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12 ):1542 [15611446.001]
  • [Cites] Br J Dermatol. 2004 Oct;151(4):837-45 [15491425.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] Anticancer Drugs. 2006 Oct;17(9):1095-8 [17001184.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Lasers Surg Med. 2007 Apr;39(4):302-10 [17457834.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):15-23 [17126738.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):843-5 [11069469.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Feb;4(2):132-6 [16503940.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Int J Dermatol. 2005 May;44(5):428-34 [15869545.001]
  • (PMID = 19322549.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 77
  •  go-up   go-down


95. Sewell LD, Marks VJ: Excision of a peristomal basal cell carcinoma using Mohs micrographic surgery. Dermatol Surg; 2008 Jul;34(7):971-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excision of a peristomal basal cell carcinoma using Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Colostomy / adverse effects. Mohs Surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384605.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Daya-Grosjean L, Sarasin A: The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res; 2005 Apr 1;571(1-2):43-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors.
  • Xeroderma pigmentosum (XP), a rare hereditary syndrome, is characterized by a hypersensitivity to solar irradiation due to a defect in nucleotide excision repair resulting in a predisposition to squamous and basal cell carcinomas as well as malignant melanomas appearing at a very early age.
  • The mutator phenotype of XP cells is evident by the higher levels of UV specific modifications found in key regulatory genes in XP skin tumors compared to those in the same tumor types from the normal population.
  • Thus, XP provides a unique model for the study of unrepaired DNA lesions, mutations and skin carcinogenesis.
  • The high level of ras oncogene activation, Ink4a-Arf and p53 tumor suppressor gene modifications as well as alterations of the different partners of the mitogenic sonic hedgehog signaling pathway (patched, smoothened and sonic hedgehog), characterized in XP skin tumors have clearly demonstrated the major role of the UV component of sunlight in the development of skin tumors.
  • These characteristics are also found in the same genes modified in sporadic skin cancers but with lower frequencies confirming the validity of studying the XP model.
  • The knowledge gained by studying XP tumors has given us a greater perception of the contribution of genetic predisposition to cancer as well as the consequences of the many alterations which modulate the activities of different genes affecting crucial pathways vital for maintaining cell homeostasis.
  • [MeSH-major] Genes, Tumor Suppressor. Neoplasms, Radiation-Induced / genetics. Oncogenes. Skin Neoplasms / genetics. Ultraviolet Rays. Xeroderma Pigmentosum / genetics

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748637.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 77
  •  go-up   go-down


97. de Ravel TJ, Ameye L, Ballon K, Borghgraef M, Vermeesch JR, Devriendt K: Early detection of chromosome 9q22.32q31.1 microdeletion and the nevoid basal cell carcinoma syndrome. Eur J Med Genet; 2009 Mar-Jun;52(2-3):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of chromosome 9q22.32q31.1 microdeletion and the nevoid basal cell carcinoma syndrome.
  • We report on a patient with a microdeletion of chromosome region 9q22.32q31.1 including the PTCH1 gene (human homologue of the Drosophila patched 1 gene), review the findings in the reported patients with similar array CGH findings, and highlight the non nevoid basal cell carcinoma/non-Gorlin syndrome findings at an earlier age.
  • These features should alert the physician to an early diagnosis of the microdeletion and allow the initiation of essential clinical management hereof.
  • [MeSH-minor] Abnormalities, Multiple / genetics. Carcinoma, Basal Cell / genetics. Humans. Infant. Intellectual Disability. Male. Motor Skills Disorders. Receptors, Cell Surface / genetics. Speech Disorders. Syndrome

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233320.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


98. Kolm I, Hofbauer G, Braun RP: [Early diagnosis of skin cancer]. Ther Umsch; 2010 Sep;67(9):439-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early diagnosis of skin cancer].
  • The skin is the most affected organ by cancer.
  • The incidence rates of skin cancer are steadily increasing, both for melanoma and non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma).
  • Over 90 % of the death cases from skin cancers attribute to melanoma.
  • In the last years a number of new non invasive techniques for the early diagnosis of melanoma have been developed which are superior to the naked eye examination.
  • In this overview article we present some non-invasive diagnostic techniques like total body photography, digital dermoscopy and confocal microscopy which in addition to dermoscopy assist the dermatologist in differentiating nevi from early melanomas.Non-melanoma skin cancer can be prevented by accurate sun protection.
  • Early squamous cell carcinomas and basal cell carcinomas can be treated either invasively or non-invasively with excellent prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / prevention & control. Melanoma / diagnosis. Melanoma / prevention & control. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control
  • [MeSH-minor] Dermoscopy. Early Diagnosis. Humans. Microscopy, Confocal. Photography. Risk Factors. Skin / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806172.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


99. Zhang X, Egawa K, Xie Y, Ihn H: The expression of SnoN in normal human skin and cutaneous keratinous neoplasms. Int J Dermatol; 2009 Jun;48(6):579-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of SnoN in normal human skin and cutaneous keratinous neoplasms.
  • It has been revealed that SnoN plays a role in the regulation of cell growth, vertebrate development, and tumorigenesis.
  • This study investigated the expression and significance of SnoN protein in normal human skin and in the development of seborrheic keratosis (SK), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC) of the skin.
  • METHODS: Six frozen sections of normal human skin, three of SK (acanthotic type), six of BCC, six of intraepidermal SCC (actinic keratosis, AK), and six each of poorly and well-differentiated SCC were immunohistochemically stained with a polyclonal antibody against SnoN.
  • RESULTS: In normal epidermis, strong positive staining was observed in the suprabasal layers, whereas the basal cell layer was entirely unstained.
  • Expression was observed in tumor cells with a squamoid phenotype in SK, but not in BCC.
  • In intraepidermal SCC, although a strong signal was seen in the well-differentiated keratinocytes of the superficial epidermal cell layers, no signal was seen in the poorly differentiated atypical cells situated in the lower epidermis.
  • CONCLUSIONS: On the basis of our results, it is suggested that SnoN is involved in differentiation in normal skin and benign and nonmetastatic skin tumors, but plays a proto-oncogenic role in undifferentiated SCC.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Keratosis, Actinic / metabolism. Proto-Oncogene Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Cell Differentiation. Dermis / metabolism. Dermis / pathology. Epidermis / metabolism. Epidermis / pathology. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Immunohistochemistry. Sweat Glands / metabolism. Sweat Glands / pathology


100. Martins E, Freitas-Junior R, Curado MP, Freitas NM, De Oliveira JC, Silva CM: [Temporal evolution of breast cancer stages in a population-based cancer registry in the Brazilian central region]. Rev Bras Ginecol Obstet; 2009 May;31(5):219-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporal evolution of breast cancer stages in a population-based cancer registry in the Brazilian central region].
  • [Transliterated title] Evolução temporal dos estádios do câncer de mama ao diagnóstico em um registro de base populacional no Brasil central.
  • PURPOSE: To analyze the temporal changes of breast cancer staging at diagnosis among women living in Goiânia, Goiás, Brazil, between 1989 and 2003.
  • METHODS: Retrospective and descriptive study in which the cases were identified from the Population-Based Cancer Registry of Goiânia for the period from 1989 to 2003.
  • The variables studied were age, diagnostic method, topographic sublocation, morphology and breast cancer staging.
  • RESULTS: A total of 3,204 breast cancer cases were collected.
  • With regard to clinical staging, 45.6% of the cases were found to be localized in the breast, with an increased rate of 19.25% between the first and the third five-year period (p<0.001; CI 95%=0.14-0.23) and 10.2% of cases were with distant metastases.
  • However, a reduction of 17.74% for metastatic cases in the same interval (p<0.001 e CI 95%=0.14-21) was observed.
  • The in situ case rate was 0.2% in 1989-1993 and increased to 6.2% in 1999-2003 (p<0.001, IC95%=4.9-7.4).
  • CONCLUSION: The diagnostic profile of breast cancer in the city of Goiânia is changing.
  • Substantial increases in the number of early breast cancer cases are being found in relation to the number of advanced cases.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Brazil. Female. Humans. Middle Aged. Neoplasm Staging. Registries. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669028.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down






Advertisement